Motif 181 (n=111)
Position-wise Probabilities
Download
| uniprot | genes | site | source | protein | function |
|---|---|---|---|---|---|
| H0Y626 | None | S31 | ochoa | RING-type E3 ubiquitin transferase (EC 2.3.2.27) | None |
| K7EQG2 | None | S39 | ochoa | Uncharacterized protein | None |
| O00267 | SUPT5H | S782 | ochoa|psp | Transcription elongation factor SPT5 (hSPT5) (DRB sensitivity-inducing factor 160 kDa subunit) (DSIF p160) (DRB sensitivity-inducing factor large subunit) (DSIF large subunit) (Tat-cotransactivator 1 protein) (Tat-CT1 protein) | Component of the DRB sensitivity-inducing factor complex (DSIF complex), which regulates mRNA processing and transcription elongation by RNA polymerase II (PubMed:10075709, PubMed:10199401, PubMed:10421630, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). DSIF positively regulates mRNA capping by stimulating the mRNA guanylyltransferase activity of RNGTT/CAP1A (PubMed:10075709, PubMed:10421630, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). DSIF also acts cooperatively with the negative elongation factor complex (NELF complex) to enhance transcriptional pausing at sites proximal to the promoter (PubMed:10075709, PubMed:10199401, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). Transcriptional pausing may facilitate the assembly of an elongation competent RNA polymerase II complex (PubMed:10075709, PubMed:10199401, PubMed:10421630, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). DSIF and NELF promote pausing by inhibition of the transcription elongation factor TFIIS/S-II (PubMed:16214896). TFIIS/S-II binds to RNA polymerase II at transcription pause sites and stimulates the weak intrinsic nuclease activity of the enzyme (PubMed:16214896). Cleavage of blocked transcripts by RNA polymerase II promotes the resumption of transcription from the new 3' terminus and may allow repeated attempts at transcription through natural pause sites (PubMed:16214896). Following phosphorylation by CDK9, DSIF can also positively regulate transcriptional elongation (PubMed:16427012). Required for the efficient activation of transcriptional elongation by the HIV-1 nuclear transcriptional activator, Tat (PubMed:10393184, PubMed:10454543, PubMed:11809800, PubMed:9514752). DSIF acts to suppress transcriptional pausing in transcripts derived from the HIV-1 LTR and blocks premature release of HIV-1 transcripts at terminator sequences (PubMed:11112772, PubMed:14701750). {ECO:0000269|PubMed:10075709, ECO:0000269|PubMed:10199401, ECO:0000269|PubMed:10393184, ECO:0000269|PubMed:10421630, ECO:0000269|PubMed:10454543, ECO:0000269|PubMed:10757782, ECO:0000269|PubMed:10912001, ECO:0000269|PubMed:11112772, ECO:0000269|PubMed:11553615, ECO:0000269|PubMed:11809800, ECO:0000269|PubMed:12653964, ECO:0000269|PubMed:12718890, ECO:0000269|PubMed:14701750, ECO:0000269|PubMed:15136722, ECO:0000269|PubMed:15380072, ECO:0000269|PubMed:16214896, ECO:0000269|PubMed:16427012, ECO:0000269|PubMed:9450929, ECO:0000269|PubMed:9514752, ECO:0000269|PubMed:9857195}. |
| O00267 | SUPT5H | S789 | ochoa | Transcription elongation factor SPT5 (hSPT5) (DRB sensitivity-inducing factor 160 kDa subunit) (DSIF p160) (DRB sensitivity-inducing factor large subunit) (DSIF large subunit) (Tat-cotransactivator 1 protein) (Tat-CT1 protein) | Component of the DRB sensitivity-inducing factor complex (DSIF complex), which regulates mRNA processing and transcription elongation by RNA polymerase II (PubMed:10075709, PubMed:10199401, PubMed:10421630, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). DSIF positively regulates mRNA capping by stimulating the mRNA guanylyltransferase activity of RNGTT/CAP1A (PubMed:10075709, PubMed:10421630, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). DSIF also acts cooperatively with the negative elongation factor complex (NELF complex) to enhance transcriptional pausing at sites proximal to the promoter (PubMed:10075709, PubMed:10199401, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). Transcriptional pausing may facilitate the assembly of an elongation competent RNA polymerase II complex (PubMed:10075709, PubMed:10199401, PubMed:10421630, PubMed:10757782, PubMed:10912001, PubMed:11112772, PubMed:11553615, PubMed:12653964, PubMed:12718890, PubMed:15136722, PubMed:15380072, PubMed:9450929, PubMed:9857195). DSIF and NELF promote pausing by inhibition of the transcription elongation factor TFIIS/S-II (PubMed:16214896). TFIIS/S-II binds to RNA polymerase II at transcription pause sites and stimulates the weak intrinsic nuclease activity of the enzyme (PubMed:16214896). Cleavage of blocked transcripts by RNA polymerase II promotes the resumption of transcription from the new 3' terminus and may allow repeated attempts at transcription through natural pause sites (PubMed:16214896). Following phosphorylation by CDK9, DSIF can also positively regulate transcriptional elongation (PubMed:16427012). Required for the efficient activation of transcriptional elongation by the HIV-1 nuclear transcriptional activator, Tat (PubMed:10393184, PubMed:10454543, PubMed:11809800, PubMed:9514752). DSIF acts to suppress transcriptional pausing in transcripts derived from the HIV-1 LTR and blocks premature release of HIV-1 transcripts at terminator sequences (PubMed:11112772, PubMed:14701750). {ECO:0000269|PubMed:10075709, ECO:0000269|PubMed:10199401, ECO:0000269|PubMed:10393184, ECO:0000269|PubMed:10421630, ECO:0000269|PubMed:10454543, ECO:0000269|PubMed:10757782, ECO:0000269|PubMed:10912001, ECO:0000269|PubMed:11112772, ECO:0000269|PubMed:11553615, ECO:0000269|PubMed:11809800, ECO:0000269|PubMed:12653964, ECO:0000269|PubMed:12718890, ECO:0000269|PubMed:14701750, ECO:0000269|PubMed:15136722, ECO:0000269|PubMed:15380072, ECO:0000269|PubMed:16214896, ECO:0000269|PubMed:16427012, ECO:0000269|PubMed:9450929, ECO:0000269|PubMed:9514752, ECO:0000269|PubMed:9857195}. |
| O15439 | ABCC4 | S661 | ochoa | ATP-binding cassette sub-family C member 4 (EC 7.6.2.-) (EC 7.6.2.2) (EC 7.6.2.3) (MRP/cMOAT-related ABC transporter) (Multi-specific organic anion transporter B) (MOAT-B) (Multidrug resistance-associated protein 4) | ATP-dependent transporter of the ATP-binding cassette (ABC) family that actively extrudes physiological compounds and xenobiotics from cells. Transports a range of endogenous molecules that have a key role in cellular communication and signaling, including cyclic nucleotides such as cyclic AMP (cAMP) and cyclic GMP (cGMP), bile acids, steroid conjugates, urate, and prostaglandins (PubMed:11856762, PubMed:12523936, PubMed:12835412, PubMed:12883481, PubMed:15364914, PubMed:15454390, PubMed:16282361, PubMed:17959747, PubMed:18300232, PubMed:26721430). Mediates the ATP-dependent efflux of glutathione conjugates such as leukotriene C4 (LTC4) and leukotriene B4 (LTB4) too. The presence of GSH is necessary for the ATP-dependent transport of LTB4, whereas GSH is not required for the transport of LTC4 (PubMed:17959747). Mediates the cotransport of bile acids with reduced glutathione (GSH) (PubMed:12523936, PubMed:12883481, PubMed:16282361). Transports a wide range of drugs and their metabolites, including anticancer, antiviral and antibiotics molecules (PubMed:11856762, PubMed:12105214, PubMed:15454390, PubMed:17344354, PubMed:18300232). Confers resistance to anticancer agents such as methotrexate (PubMed:11106685). {ECO:0000269|PubMed:11106685, ECO:0000269|PubMed:11856762, ECO:0000269|PubMed:12105214, ECO:0000269|PubMed:12523936, ECO:0000269|PubMed:12835412, ECO:0000269|PubMed:12883481, ECO:0000269|PubMed:15364914, ECO:0000269|PubMed:15454390, ECO:0000269|PubMed:16282361, ECO:0000269|PubMed:17344354, ECO:0000269|PubMed:17959747, ECO:0000269|PubMed:18300232, ECO:0000269|PubMed:26721430}. |
| O43524 | FOXO3 | S432 | ochoa | Forkhead box protein O3 (AF6q21 protein) (Forkhead in rhabdomyosarcoma-like 1) | Transcriptional activator that recognizes and binds to the DNA sequence 5'-[AG]TAAA[TC]A-3' and regulates different processes, such as apoptosis and autophagy (PubMed:10102273, PubMed:16751106, PubMed:21329882, PubMed:30513302). Acts as a positive regulator of autophagy in skeletal muscle: in starved cells, enters the nucleus following dephosphorylation and binds the promoters of autophagy genes, such as GABARAP1L, MAP1LC3B and ATG12, thereby activating their expression, resulting in proteolysis of skeletal muscle proteins (By similarity). Triggers apoptosis in the absence of survival factors, including neuronal cell death upon oxidative stress (PubMed:10102273, PubMed:16751106). Participates in post-transcriptional regulation of MYC: following phosphorylation by MAPKAPK5, promotes induction of miR-34b and miR-34c expression, 2 post-transcriptional regulators of MYC that bind to the 3'UTR of MYC transcript and prevent its translation (PubMed:21329882). In response to metabolic stress, translocates into the mitochondria where it promotes mtDNA transcription (PubMed:23283301). In response to metabolic stress, translocates into the mitochondria where it promotes mtDNA transcription. Also acts as a key regulator of chondrogenic commitment of skeletal progenitor cells in response to lipid availability: when lipids levels are low, translocates to the nucleus and promotes expression of SOX9, which induces chondrogenic commitment and suppresses fatty acid oxidation (By similarity). Also acts as a key regulator of regulatory T-cells (Treg) differentiation by activating expression of FOXP3 (PubMed:30513302). {ECO:0000250|UniProtKB:Q9WVH4, ECO:0000269|PubMed:10102273, ECO:0000269|PubMed:16751106, ECO:0000269|PubMed:21329882, ECO:0000269|PubMed:23283301, ECO:0000269|PubMed:30513302}. |
| O60244 | MED14 | S1116 | ochoa | Mediator of RNA polymerase II transcription subunit 14 (Activator-recruited cofactor 150 kDa component) (ARC150) (Cofactor required for Sp1 transcriptional activation subunit 2) (CRSP complex subunit 2) (Mediator complex subunit 14) (RGR1 homolog) (hRGR1) (Thyroid hormone receptor-associated protein complex 170 kDa component) (Trap170) (Transcriptional coactivator CRSP150) (Vitamin D3 receptor-interacting protein complex 150 kDa component) (DRIP150) | Component of the Mediator complex, a coactivator involved in the regulated transcription of nearly all RNA polymerase II-dependent genes. Mediator functions as a bridge to convey information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. Mediator is recruited to promoters by direct interactions with regulatory proteins and serves as a scaffold for the assembly of a functional preinitiation complex with RNA polymerase II and the general transcription factors. {ECO:0000269|PubMed:15340088, ECO:0000269|PubMed:15625066, ECO:0000269|PubMed:16595664}. |
| O60315 | ZEB2 | S738 | ochoa | Zinc finger E-box-binding homeobox 2 (Smad-interacting protein 1) (SMADIP1) (Zinc finger homeobox protein 1b) | Transcriptional inhibitor that binds to DNA sequence 5'-CACCT-3' in different promoters (PubMed:16061479, PubMed:20516212). Represses transcription of E-cadherin (PubMed:16061479). Represses expression of MEOX2 (PubMed:20516212). {ECO:0000269|PubMed:16061479, ECO:0000269|PubMed:20516212}. |
| O60885 | BRD4 | S488 | psp | Bromodomain-containing protein 4 (Protein HUNK1) | Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation (PubMed:20871596, PubMed:23086925, PubMed:23317504, PubMed:29176719, PubMed:29379197). Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure (PubMed:22334664, PubMed:23317504, PubMed:23589332). During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters (PubMed:16109376, PubMed:16109377, PubMed:19596240, PubMed:23589332, PubMed:24360279). Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6 (PubMed:16109376, PubMed:16109377, PubMed:19596240, PubMed:23589332, PubMed:24360279). BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II (PubMed:16109376, PubMed:16109377, PubMed:19596240, PubMed:23589332, PubMed:24360279). Regulates differentiation of naive CD4(+) T-cells into T-helper Th17 by promoting recruitment of P-TEFb to promoters (By similarity). Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II (PubMed:23086925). According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo (PubMed:22509028). In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B (PubMed:19103749). Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters (PubMed:23317504). {ECO:0000250|UniProtKB:Q9ESU6, ECO:0000269|PubMed:16109376, ECO:0000269|PubMed:16109377, ECO:0000269|PubMed:19103749, ECO:0000269|PubMed:19596240, ECO:0000269|PubMed:22334664, ECO:0000269|PubMed:22509028, ECO:0000269|PubMed:23086925, ECO:0000269|PubMed:23317504, ECO:0000269|PubMed:23589332, ECO:0000269|PubMed:24360279, ECO:0000269|PubMed:29176719}.; FUNCTION: [Isoform B]: Acts as a chromatin insulator in the DNA damage response pathway. Inhibits DNA damage response signaling by recruiting the condensin-2 complex to acetylated histones, leading to chromatin structure remodeling, insulating the region from DNA damage response by limiting spreading of histone H2AX/H2A.x phosphorylation. {ECO:0000269|PubMed:23728299}. |
| O75376 | NCOR1 | S2102 | ochoa | Nuclear receptor corepressor 1 (N-CoR) (N-CoR1) | Mediates transcriptional repression by certain nuclear receptors (PubMed:20812024). Part of a complex which promotes histone deacetylation and the formation of repressive chromatin structures which may impede the access of basal transcription factors. Participates in the transcriptional repressor activity produced by BCL6. Recruited by ZBTB7A to the androgen response elements/ARE on target genes, negatively regulates androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Mediates the NR1D1-dependent repression and circadian regulation of TSHB expression (By similarity). The NCOR1-HDAC3 complex regulates the circadian expression of the core clock gene ARTNL/BMAL1 and the genes involved in lipid metabolism in the liver (By similarity). {ECO:0000250|UniProtKB:Q60974, ECO:0000269|PubMed:14527417, ECO:0000269|PubMed:20812024}. |
| O75376 | NCOR1 | S2109 | ochoa | Nuclear receptor corepressor 1 (N-CoR) (N-CoR1) | Mediates transcriptional repression by certain nuclear receptors (PubMed:20812024). Part of a complex which promotes histone deacetylation and the formation of repressive chromatin structures which may impede the access of basal transcription factors. Participates in the transcriptional repressor activity produced by BCL6. Recruited by ZBTB7A to the androgen response elements/ARE on target genes, negatively regulates androgen receptor signaling and androgen-induced cell proliferation (PubMed:20812024). Mediates the NR1D1-dependent repression and circadian regulation of TSHB expression (By similarity). The NCOR1-HDAC3 complex regulates the circadian expression of the core clock gene ARTNL/BMAL1 and the genes involved in lipid metabolism in the liver (By similarity). {ECO:0000250|UniProtKB:Q60974, ECO:0000269|PubMed:14527417, ECO:0000269|PubMed:20812024}. |
| O75381 | PEX14 | S265 | ochoa | Peroxisomal membrane protein PEX14 (PTS1 receptor-docking protein) (Peroxin-14) (Peroxisomal membrane anchor protein PEX14) | Component of the PEX13-PEX14 docking complex, a translocon channel that specifically mediates the import of peroxisomal cargo proteins bound to PEX5 receptor (PubMed:24235149, PubMed:28765278, PubMed:9653144). The PEX13-PEX14 docking complex forms a large import pore which can be opened to a diameter of about 9 nm (By similarity). Mechanistically, PEX5 receptor along with cargo proteins associates with the PEX14 subunit of the PEX13-PEX14 docking complex in the cytosol, leading to the insertion of the receptor into the organelle membrane with the concomitant translocation of the cargo into the peroxisome matrix (PubMed:24235149, PubMed:28765278). Plays a key role for peroxisome movement through a direct interaction with tubulin (PubMed:21525035). {ECO:0000250|UniProtKB:P53112, ECO:0000269|PubMed:21525035, ECO:0000269|PubMed:24235149, ECO:0000269|PubMed:28765278, ECO:0000269|PubMed:9653144}. |
| O75962 | TRIO | S2499 | ochoa | Triple functional domain protein (EC 2.7.11.1) (PTPRF-interacting protein) | Guanine nucleotide exchange factor (GEF) for RHOA and RAC1 GTPases (PubMed:22155786, PubMed:27418539, PubMed:8643598). Involved in coordinating actin remodeling, which is necessary for cell migration and growth (PubMed:10341202, PubMed:22155786). Plays a key role in the regulation of neurite outgrowth and lamellipodia formation (PubMed:32109419). In developing hippocampal neurons, limits dendrite formation, without affecting the establishment of axon polarity. Once dendrites are formed, involved in the control of synaptic function by regulating the endocytosis of AMPA-selective glutamate receptors (AMPARs) at CA1 excitatory synapses (By similarity). May act as a regulator of adipogenesis (By similarity). {ECO:0000250|UniProtKB:F1M0Z1, ECO:0000269|PubMed:10341202, ECO:0000269|PubMed:22155786, ECO:0000269|PubMed:27418539, ECO:0000269|PubMed:32109419, ECO:0000269|PubMed:8643598}. |
| O94929 | ABLIM3 | S476 | ochoa | Actin-binding LIM protein 3 (abLIM-3) (Actin-binding LIM protein family member 3) | May act as scaffold protein. May stimulate ABRA activity and ABRA-dependent SRF transcriptional activity. {ECO:0000269|PubMed:17194709}. |
| O95361 | TRIM16 | S31 | ochoa | Tripartite motif-containing protein 16 (EC 2.3.2.27) (E3 ubiquitin-protein ligase TRIM16) (Estrogen-responsive B box protein) | E3 ubiquitin ligase that plays an essential role in the organization of autophagic response and ubiquitination upon lysosomal and phagosomal damages. Plays a role in the stress-induced biogenesis and degradation of protein aggresomes by regulating the p62-KEAP1-NRF2 signaling and particularly by modulating the ubiquitination levels and thus stability of NRF2. Acts as a scaffold protein and facilitates autophagic degradation of protein aggregates by interacting with p62/SQSTM, ATG16L1 and LC3B/MAP1LC3B. In turn, protects the cell against oxidative stress-induced cell death as a consequence of endomembrane damage. {ECO:0000269|PubMed:22629402, ECO:0000269|PubMed:27693506, ECO:0000269|PubMed:30143514}. |
| O95425 | SVIL | S263 | ochoa | Supervillin (Archvillin) (p205/p250) | [Isoform 1]: Forms a high-affinity link between the actin cytoskeleton and the membrane. Is among the first costameric proteins to assemble during myogenesis and it contributes to myogenic membrane structure and differentiation (PubMed:12711699). Appears to be involved in myosin II assembly. May modulate myosin II regulation through MLCK during cell spreading, an initial step in cell migration. May play a role in invadopodial function (PubMed:19109420). {ECO:0000269|PubMed:12711699, ECO:0000269|PubMed:19109420}.; FUNCTION: [Isoform 2]: May be involved in modulation of focal adhesions. Supervillin-mediated down-regulation of focal adhesions involves binding to TRIP6. Plays a role in cytokinesis through KIF14 interaction (By similarity). {ECO:0000250|UniProtKB:O46385}. |
| O95817 | BAG3 | S191 | ochoa | BAG family molecular chaperone regulator 3 (BAG-3) (Bcl-2-associated athanogene 3) (Bcl-2-binding protein Bis) (Docking protein CAIR-1) | Co-chaperone and adapter protein that connects different classes of molecular chaperones including heat shock proteins 70 (HSP70s), e.g. HSPA1A/HSP70 or HSPA8/HSC70, and small heat shock proteins (sHSPs), e.g. HSPB8 (PubMed:27884606, PubMed:30559338). Acts as a nucleotide-exchange factor (NEF) promoting the release of ADP from HSP70s, thereby triggering client protein release (PubMed:27884606, PubMed:30559338). Nucleotide release is mediated via BAG3 binding to the nucleotide-binding domain (NBD) of HSP70s, whereas client release is mediated via binding to the substrate-binding domain (SBD) (PubMed:27474739, PubMed:9873016). Has anti-apoptotic activity (PubMed:10597216). Plays a role in the HSF1 nucleocytoplasmic transport (PubMed:26159920). {ECO:0000269|PubMed:10597216, ECO:0000269|PubMed:24318877, ECO:0000269|PubMed:26159920, ECO:0000269|PubMed:27474739, ECO:0000269|PubMed:27884606, ECO:0000269|PubMed:30559338, ECO:0000269|PubMed:9873016}. |
| P08651 | NFIC | S477 | ochoa | Nuclear factor 1 C-type (NF1-C) (Nuclear factor 1/C) (CCAAT-box-binding transcription factor) (CTF) (Nuclear factor I/C) (NF-I/C) (NFI-C) (TGGCA-binding protein) | Recognizes and binds the palindromic sequence 5'-TTGGCNNNNNGCCAA-3' present in viral and cellular promoters and in the origin of replication of adenovirus type 2. These proteins are individually capable of activating transcription and replication. |
| P10636 | MAPT | S512 | ochoa | Microtubule-associated protein tau (Neurofibrillary tangle protein) (Paired helical filament-tau) (PHF-tau) | Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity (PubMed:21985311). The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both (PubMed:21985311, PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. {ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:32961270}. |
| P10636 | MAPT | S519 | ochoa|psp | Microtubule-associated protein tau (Neurofibrillary tangle protein) (Paired helical filament-tau) (PHF-tau) | Promotes microtubule assembly and stability, and might be involved in the establishment and maintenance of neuronal polarity (PubMed:21985311). The C-terminus binds axonal microtubules while the N-terminus binds neural plasma membrane components, suggesting that tau functions as a linker protein between both (PubMed:21985311, PubMed:32961270). Axonal polarity is predetermined by TAU/MAPT localization (in the neuronal cell) in the domain of the cell body defined by the centrosome. The short isoforms allow plasticity of the cytoskeleton whereas the longer isoforms may preferentially play a role in its stabilization. {ECO:0000269|PubMed:21985311, ECO:0000269|PubMed:32961270}. |
| P15923 | TCF3 | S345 | ochoa | Transcription factor E2-alpha (Class B basic helix-loop-helix protein 21) (bHLHb21) (Immunoglobulin enhancer-binding factor E12/E47) (Immunoglobulin transcription factor 1) (Kappa-E2-binding factor) (Transcription factor 3) (TCF-3) (Transcription factor ITF-1) | Transcriptional regulator involved in the initiation of neuronal differentiation and mesenchymal to epithelial transition (By similarity). Heterodimers between TCF3 and tissue-specific basic helix-loop-helix (bHLH) proteins play major roles in determining tissue-specific cell fate during embryogenesis, like muscle or early B-cell differentiation (By similarity). Together with TCF15, required for the mesenchymal to epithelial transition (By similarity). Dimers bind DNA on E-box motifs: 5'-CANNTG-3' (By similarity). Binds to the kappa-E2 site in the kappa immunoglobulin gene enhancer (PubMed:2493990). Binds to IEB1 and IEB2, which are short DNA sequences in the insulin gene transcription control region (By similarity). {ECO:0000250|UniProtKB:P15806, ECO:0000269|PubMed:2493990}.; FUNCTION: [Isoform E47]: Facilitates ATOH7 binding to DNA at the consensus sequence 5'-CAGGTG-3', and positively regulates transcriptional activity. {ECO:0000269|PubMed:31696227}. |
| P15941 | MUC1 | S1227 | ochoa|psp | Mucin-1 (MUC-1) (Breast carcinoma-associated antigen DF3) (Cancer antigen 15-3) (CA 15-3) (Carcinoma-associated mucin) (Episialin) (H23AG) (Krebs von den Lungen-6) (KL-6) (PEMT) (Peanut-reactive urinary mucin) (PUM) (Polymorphic epithelial mucin) (PEM) (Tumor-associated epithelial membrane antigen) (EMA) (Tumor-associated mucin) (CD antigen CD227) [Cleaved into: Mucin-1 subunit alpha (MUC1-NT) (MUC1-alpha); Mucin-1 subunit beta (MUC1-beta) (MUC1-CT)] | The alpha subunit has cell adhesive properties. Can act both as an adhesion and an anti-adhesion protein. May provide a protective layer on epithelial cells against bacterial and enzyme attack.; FUNCTION: The beta subunit contains a C-terminal domain which is involved in cell signaling, through phosphorylations and protein-protein interactions. Modulates signaling in ERK, SRC and NF-kappa-B pathways. In activated T-cells, influences directly or indirectly the Ras/MAPK pathway. Promotes tumor progression. Regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. Binds, together with KLF4, the PE21 promoter element of TP53 and represses TP53 activity. |
| P24928 | POLR2A | S1616 | psp | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | T1840 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1847 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | T1854 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1861 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1868 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1875 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1882 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1889 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1896 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | T1903 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1910 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1917 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1924 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1931 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P24928 | POLR2A | S1938 | ochoa | DNA-directed RNA polymerase II subunit RPB1 (RNA polymerase II subunit B1) (EC 2.7.7.6) (3'-5' exoribonuclease) (EC 3.1.13.-) (DNA-directed RNA polymerase II subunit A) (DNA-directed RNA polymerase III largest subunit) (RNA-directed RNA polymerase II subunit RPB1) (EC 2.7.7.48) | Catalytic core component of RNA polymerase II (Pol II), a DNA-dependent RNA polymerase which synthesizes mRNA precursors and many functional non-coding RNAs using the four ribonucleoside triphosphates as substrates (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:30190596, PubMed:9852112). Pol II-mediated transcription cycle proceeds through transcription initiation, transcription elongation and transcription termination stages. During transcription initiation, Pol II pre-initiation complex (PIC) is recruited to DNA promoters, with focused-type promoters containing either the initiator (Inr) element, or the TATA-box found in cell-type specific genes and dispersed-type promoters that often contain hypomethylated CpG islands usually found in housekeeping genes. Once the polymerase has escaped from the promoter it enters the elongation phase during which RNA is actively polymerized, based on complementarity with the template DNA strand. Transcription termination involves the release of the RNA transcript and polymerase from the DNA (By similarity) (PubMed:23748380, PubMed:27193682, PubMed:28108474, PubMed:30190596, PubMed:9852112). Forms Pol II active center together with the second largest subunit POLR2B/RPB2. Appends one nucleotide at a time to the 3' end of the nascent RNA, with POLR2A/RPB1 most likely contributing a Mg(2+)-coordinating DxDGD motif, and POLR2B/RPB2 participating in the coordination of a second Mg(2+) ion and providing lysine residues believed to facilitate Watson-Crick base pairing between the incoming nucleotide and template base. Typically, Mg(2+) ions direct a 5' nucleoside triphosphate to form a phosphodiester bond with the 3' hydroxyl of the preceding nucleotide of the nascent RNA, with the elimination of pyrophosphate. The reversible pyrophosphorolysis can occur at high pyrophosphate concentrations (By similarity) (PubMed:30190596, PubMed:8381534, PubMed:9852112). Can proofread the nascent RNA transcript by means of a 3' -> 5' exonuclease activity. If a ribonucleotide is mis-incorporated, backtracks along the template DNA and cleaves the phosphodiester bond releasing the mis-incorporated 5'-ribonucleotide (By similarity) (PubMed:8381534). Through its unique C-terminal domain (CTD, 52 heptapeptide tandem repeats) serves as a platform for assembly of factors that regulate transcription initiation, elongation and termination. CTD phosphorylation on Ser-5 mediates Pol II promoter escape, whereas phosphorylation on Ser-2 is required for Pol II pause release during transcription elongation and further pre-mRNA processing. Additionally, the regulation of gene expression levels depends on the balance between methylation and acetylation levels of the CTD-lysines. Initiation or early elongation steps of transcription of growth-factor-induced immediate early genes are regulated by the acetylation status of the CTD. Methylation and dimethylation have a repressive effect on target genes expression. Cooperates with mRNA splicing machinery in co-transcriptional 5'-end capping and co-transcriptional splicing of pre-mRNA (By similarity) (PubMed:24207025, PubMed:26124092). {ECO:0000250|UniProtKB:G3MZY8, ECO:0000250|UniProtKB:P08775, ECO:0000269|PubMed:23748380, ECO:0000269|PubMed:24207025, ECO:0000269|PubMed:26124092, ECO:0000269|PubMed:27193682, ECO:0000269|PubMed:28108474, ECO:0000269|PubMed:30190596, ECO:0000269|PubMed:8381534, ECO:0000269|PubMed:9852112}.; FUNCTION: RNA-dependent RNA polymerase that catalyzes the extension of a non-coding RNA (ncRNA) at the 3'-end using the four ribonucleoside triphosphates as substrates. An internal ncRNA sequence near the 3'-end serves as a template in a single-round Pol II-mediated RNA polymerization reaction. May decrease the stability of ncRNAs that repress Pol II-mediated gene transcription. {ECO:0000269|PubMed:23395899}.; FUNCTION: (Microbial infection) Acts as an RNA-dependent RNA polymerase when associated with small delta antigen of Hepatitis delta virus, acting both as a replicase and transcriptase for the viral RNA circular genome. {ECO:0000269|PubMed:18032511}. |
| P25440 | BRD2 | S305 | ochoa | Bromodomain-containing protein 2 (O27.1.1) | Chromatin reader protein that specifically recognizes and binds histone H4 acetylated at 'Lys-5' and 'Lys-12' (H4K5ac and H4K12ac, respectively), thereby controlling gene expression and remodeling chromatin structures (PubMed:17148447, PubMed:17848202, PubMed:18406326, PubMed:20048151, PubMed:20709061, PubMed:20871596). Recruits transcription factors and coactivators to target gene sites, and activates RNA polymerase II machinery for transcriptional elongation (PubMed:28262505). Plays a key role in genome compartmentalization via its association with CTCF and cohesin: recruited to chromatin by CTCF and promotes formation of topologically associating domains (TADs) via its ability to bind acetylated histones, contributing to CTCF boundary formation and enhancer insulation (PubMed:35410381). Also recognizes and binds acetylated non-histone proteins, such as STAT3 (PubMed:28262505). Involved in inflammatory response by regulating differentiation of naive CD4(+) T-cells into T-helper Th17: recognizes and binds STAT3 acetylated at 'Lys-87', promoting STAT3 recruitment to chromatin (PubMed:28262505). In addition to acetylated lysines, also recognizes and binds lysine residues on histones that are both methylated and acetylated on the same side chain to form N6-acetyl-N6-methyllysine (Kacme), an epigenetic mark of active chromatin associated with increased transcriptional initiation (PubMed:37731000). Specifically binds histone H4 acetyl-methylated at 'Lys-5' and 'Lys-12' (H4K5acme and H4K12acme, respectively) (PubMed:37731000). {ECO:0000269|PubMed:17148447, ECO:0000269|PubMed:17848202, ECO:0000269|PubMed:18406326, ECO:0000269|PubMed:20048151, ECO:0000269|PubMed:20709061, ECO:0000269|PubMed:20871596, ECO:0000269|PubMed:28262505, ECO:0000269|PubMed:35410381, ECO:0000269|PubMed:37731000}. |
| P33241 | LSP1 | S193 | ochoa | Lymphocyte-specific protein 1 (47 kDa actin-binding protein) (52 kDa phosphoprotein) (pp52) (Lymphocyte-specific antigen WP34) | May play a role in mediating neutrophil activation and chemotaxis. {ECO:0000250}. |
| P38159 | RBMX | S284 | ochoa | RNA-binding motif protein, X chromosome (Glycoprotein p43) (Heterogeneous nuclear ribonucleoprotein G) (hnRNP G) [Cleaved into: RNA-binding motif protein, X chromosome, N-terminally processed] | RNA-binding protein that plays several role in the regulation of pre- and post-transcriptional processes. Implicated in tissue-specific regulation of gene transcription and alternative splicing of several pre-mRNAs. Binds to and stimulates transcription from the tumor suppressor TXNIP gene promoter; may thus be involved in tumor suppression. When associated with SAFB, binds to and stimulates transcription from the SREBF1 promoter. Associates with nascent mRNAs transcribed by RNA polymerase II. Component of the supraspliceosome complex that regulates pre-mRNA alternative splice site selection. Can either activate or suppress exon inclusion; acts additively with TRA2B to promote exon 7 inclusion of the survival motor neuron SMN2. Represses the splicing of MAPT/Tau exon 10. Binds preferentially to single-stranded 5'-CC[A/C]-rich RNA sequence motifs localized in a single-stranded conformation; probably binds RNA as a homodimer. Binds non-specifically to pre-mRNAs. Also plays a role in the cytoplasmic TNFR1 trafficking pathways; promotes both the IL-1-beta-mediated inducible proteolytic cleavage of TNFR1 ectodomains and the release of TNFR1 exosome-like vesicles to the extracellular compartment. {ECO:0000269|PubMed:12165565, ECO:0000269|PubMed:12761049, ECO:0000269|PubMed:16707624, ECO:0000269|PubMed:18445477, ECO:0000269|PubMed:18541147, ECO:0000269|PubMed:19282290, ECO:0000269|PubMed:21327109}. |
| P38159 | RBMX | S291 | ochoa | RNA-binding motif protein, X chromosome (Glycoprotein p43) (Heterogeneous nuclear ribonucleoprotein G) (hnRNP G) [Cleaved into: RNA-binding motif protein, X chromosome, N-terminally processed] | RNA-binding protein that plays several role in the regulation of pre- and post-transcriptional processes. Implicated in tissue-specific regulation of gene transcription and alternative splicing of several pre-mRNAs. Binds to and stimulates transcription from the tumor suppressor TXNIP gene promoter; may thus be involved in tumor suppression. When associated with SAFB, binds to and stimulates transcription from the SREBF1 promoter. Associates with nascent mRNAs transcribed by RNA polymerase II. Component of the supraspliceosome complex that regulates pre-mRNA alternative splice site selection. Can either activate or suppress exon inclusion; acts additively with TRA2B to promote exon 7 inclusion of the survival motor neuron SMN2. Represses the splicing of MAPT/Tau exon 10. Binds preferentially to single-stranded 5'-CC[A/C]-rich RNA sequence motifs localized in a single-stranded conformation; probably binds RNA as a homodimer. Binds non-specifically to pre-mRNAs. Also plays a role in the cytoplasmic TNFR1 trafficking pathways; promotes both the IL-1-beta-mediated inducible proteolytic cleavage of TNFR1 ectodomains and the release of TNFR1 exosome-like vesicles to the extracellular compartment. {ECO:0000269|PubMed:12165565, ECO:0000269|PubMed:12761049, ECO:0000269|PubMed:16707624, ECO:0000269|PubMed:18445477, ECO:0000269|PubMed:18541147, ECO:0000269|PubMed:19282290, ECO:0000269|PubMed:21327109}. |
| P47974 | ZFP36L2 | S430 | ochoa | mRNA decay activator protein ZFP36L2 (Butyrate response factor 2) (EGF-response factor 2) (ERF-2) (TPA-induced sequence 11d) (Zinc finger protein 36, C3H1 type-like 2) (ZFP36-like 2) | Zinc-finger RNA-binding protein that destabilizes several cytoplasmic AU-rich element (ARE)-containing mRNA transcripts by promoting their poly(A) tail removal or deadenylation, and hence provide a mechanism for attenuating protein synthesis (PubMed:14981510, PubMed:25106868, PubMed:34611029). Acts as a 3'-untranslated region (UTR) ARE mRNA-binding adapter protein to communicate signaling events to the mRNA decay machinery (PubMed:25106868). Functions by recruiting the CCR4-NOT deadenylase complex and probably other components of the cytoplasmic RNA decay machinery to the bound ARE-containing mRNAs, and hence promotes ARE-mediated mRNA deadenylation and decay processes (PubMed:25106868). Binds to 3'-UTR ARE of numerous mRNAs (PubMed:14981510, PubMed:20506496, PubMed:25106868). Promotes ARE-containing mRNA decay of the low-density lipoprotein (LDL) receptor (LDLR) mRNA in response to phorbol 12-myristate 13-acetate (PMA) treatment in a p38 MAPK-dependent manner (PubMed:25106868). Positively regulates early adipogenesis by promoting ARE-mediated mRNA decay of immediate early genes (IEGs). Plays a role in mature peripheral neuron integrity by promoting ARE-containing mRNA decay of the transcriptional repressor REST mRNA. Plays a role in ovulation and oocyte meiotic maturation by promoting ARE-mediated mRNA decay of the luteinizing hormone receptor LHCGR mRNA. Acts as a negative regulator of erythroid cell differentiation: promotes glucocorticoid-induced self-renewal of erythroid cells by binding mRNAs that are induced or highly expressed during terminal erythroid differentiation and promotes their degradation, preventing erythroid cell differentiation. In association with ZFP36L1 maintains quiescence on developing B lymphocytes by promoting ARE-mediated decay of several mRNAs encoding cell cycle regulators that help B cells progress through the cell cycle, and hence ensuring accurate variable-diversity-joining (VDJ) recombination process and functional immune cell formation. Together with ZFP36L1 is also necessary for thymocyte development and prevention of T-cell acute lymphoblastic leukemia (T-ALL) transformation by promoting ARE-mediated mRNA decay of the oncogenic transcription factor NOTCH1 mRNA. {ECO:0000250|UniProtKB:P23949, ECO:0000269|PubMed:14981510, ECO:0000269|PubMed:20506496, ECO:0000269|PubMed:25106868, ECO:0000269|PubMed:34611029}. |
| P49790 | NUP153 | S192 | ochoa | Nuclear pore complex protein Nup153 (153 kDa nucleoporin) (Nucleoporin Nup153) | Component of the nuclear pore complex (NPC), a complex required for the trafficking across the nuclear envelope. Functions as a scaffolding element in the nuclear phase of the NPC essential for normal nucleocytoplasmic transport of proteins and mRNAs. Involved in the quality control and retention of unspliced mRNAs in the nucleus; in association with TPR, regulates the nuclear export of unspliced mRNA species bearing constitutive transport element (CTE) in a NXF1- and KHDRBS1-independent manner. Mediates TPR anchoring to the nuclear membrane at NPC. The repeat-containing domain may be involved in anchoring other components of the NPC to the pore membrane. Possible DNA-binding subunit of the nuclear pore complex (NPC). {ECO:0000269|PubMed:12802065, ECO:0000269|PubMed:15229283, ECO:0000269|PubMed:22253824}.; FUNCTION: (Microbial infection) Interacts with HIV-1 caspid protein P24 and thereby promotes the integration of the virus in the nucleus of non-dividing cells (in vitro). {ECO:0000269|PubMed:23523133, ECO:0000269|PubMed:24130490, ECO:0000269|PubMed:29997211}.; FUNCTION: (Microbial infection) Binds HIV-2 protein vpx and thereby promotes the nuclear translocation of the lentiviral genome (in vitro). {ECO:0000269|PubMed:24130490, ECO:0000269|PubMed:31913756}. |
| Q01484 | ANK2 | S2458 | ochoa | Ankyrin-2 (ANK-2) (Ankyrin-B) (Brain ankyrin) (Non-erythroid ankyrin) | Plays an essential role in the localization and membrane stabilization of ion transporters and ion channels in several cell types, including cardiomyocytes, as well as in striated muscle cells. In skeletal muscle, required for proper localization of DMD and DCTN4 and for the formation and/or stability of a special subset of microtubules associated with costameres and neuromuscular junctions. In cardiomyocytes, required for coordinate assembly of Na/Ca exchanger, SLC8A1/NCX1, Na/K ATPases ATP1A1 and ATP1A2 and inositol 1,4,5-trisphosphate (InsP3) receptors at sarcoplasmic reticulum/sarcolemma sites. Required for expression and targeting of SPTBN1 in neonatal cardiomyocytes and for the regulation of neonatal cardiomyocyte contraction rate (PubMed:12571597). In the inner segment of rod photoreceptors, required for the coordinated expression of the Na/K ATPase, Na/Ca exchanger and beta-2-spectrin (SPTBN1) (By similarity). Plays a role in endocytosis and intracellular protein transport. Associates with phosphatidylinositol 3-phosphate (PI3P)-positive organelles and binds dynactin to promote long-range motility of cells. Recruits RABGAP1L to (PI3P)-positive early endosomes, where RABGAP1L inactivates RAB22A, and promotes polarized trafficking to the leading edge of the migrating cells. Part of the ANK2/RABGAP1L complex which is required for the polarized recycling of fibronectin receptor ITGA5 ITGB1 to the plasma membrane that enables continuous directional cell migration (By similarity). {ECO:0000250|UniProtKB:Q8C8R3, ECO:0000269|PubMed:12571597}. |
| Q03164 | KMT2A | S3057 | ochoa | Histone-lysine N-methyltransferase 2A (Lysine N-methyltransferase 2A) (EC 2.1.1.364) (ALL-1) (CXXC-type zinc finger protein 7) (Cysteine methyltransferase KMT2A) (EC 2.1.1.-) (Myeloid/lymphoid or mixed-lineage leukemia) (Myeloid/lymphoid or mixed-lineage leukemia protein 1) (Trithorax-like protein) (Zinc finger protein HRX) [Cleaved into: MLL cleavage product N320 (N-terminal cleavage product of 320 kDa) (p320); MLL cleavage product C180 (C-terminal cleavage product of 180 kDa) (p180)] | Histone methyltransferase that plays an essential role in early development and hematopoiesis (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:26886794). Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac) (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:24235145, PubMed:26886794). Catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:25561738, PubMed:26886794). Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity (PubMed:19187761, PubMed:26886794). Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9' (PubMed:19187761). Binds to unmethylated CpG elements in the promoter of target genes and helps maintain them in the nonmethylated state (PubMed:20010842). Required for transcriptional activation of HOXA9 (PubMed:12453419, PubMed:20010842, PubMed:20677832). Promotes PPP1R15A-induced apoptosis (PubMed:10490642). Plays a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-BMAL1 heterodimer (By similarity). Establishes a permissive chromatin state for circadian transcription by mediating a rhythmic methylation of 'Lys-4' of histone H3 (H3K4me) and this histone modification directs the circadian acetylation at H3K9 and H3K14 allowing the recruitment of CLOCK-BMAL1 to chromatin (By similarity). Also has auto-methylation activity on Cys-3882 in absence of histone H3 substrate (PubMed:24235145). {ECO:0000250|UniProtKB:P55200, ECO:0000269|PubMed:10490642, ECO:0000269|PubMed:12453419, ECO:0000269|PubMed:15960975, ECO:0000269|PubMed:19187761, ECO:0000269|PubMed:19556245, ECO:0000269|PubMed:20010842, ECO:0000269|PubMed:21220120, ECO:0000269|PubMed:24235145, ECO:0000269|PubMed:26886794, ECO:0000305|PubMed:20677832}. |
| Q03164 | KMT2A | S3515 | ochoa | Histone-lysine N-methyltransferase 2A (Lysine N-methyltransferase 2A) (EC 2.1.1.364) (ALL-1) (CXXC-type zinc finger protein 7) (Cysteine methyltransferase KMT2A) (EC 2.1.1.-) (Myeloid/lymphoid or mixed-lineage leukemia) (Myeloid/lymphoid or mixed-lineage leukemia protein 1) (Trithorax-like protein) (Zinc finger protein HRX) [Cleaved into: MLL cleavage product N320 (N-terminal cleavage product of 320 kDa) (p320); MLL cleavage product C180 (C-terminal cleavage product of 180 kDa) (p180)] | Histone methyltransferase that plays an essential role in early development and hematopoiesis (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:26886794). Catalytic subunit of the MLL1/MLL complex, a multiprotein complex that mediates both methylation of 'Lys-4' of histone H3 (H3K4me) complex and acetylation of 'Lys-16' of histone H4 (H4K16ac) (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:24235145, PubMed:26886794). Catalyzes methyl group transfer from S-adenosyl-L-methionine to the epsilon-amino group of 'Lys-4' of histone H3 (H3K4) via a non-processive mechanism. Part of chromatin remodeling machinery predominantly forms H3K4me1 and H3K4me2 methylation marks at active chromatin sites where transcription and DNA repair take place (PubMed:12453419, PubMed:15960975, PubMed:19187761, PubMed:19556245, PubMed:20677832, PubMed:21220120, PubMed:25561738, PubMed:26886794). Has weak methyltransferase activity by itself, and requires other component of the MLL1/MLL complex to obtain full methyltransferase activity (PubMed:19187761, PubMed:26886794). Has no activity toward histone H3 phosphorylated on 'Thr-3', less activity toward H3 dimethylated on 'Arg-8' or 'Lys-9', while it has higher activity toward H3 acetylated on 'Lys-9' (PubMed:19187761). Binds to unmethylated CpG elements in the promoter of target genes and helps maintain them in the nonmethylated state (PubMed:20010842). Required for transcriptional activation of HOXA9 (PubMed:12453419, PubMed:20010842, PubMed:20677832). Promotes PPP1R15A-induced apoptosis (PubMed:10490642). Plays a critical role in the control of circadian gene expression and is essential for the transcriptional activation mediated by the CLOCK-BMAL1 heterodimer (By similarity). Establishes a permissive chromatin state for circadian transcription by mediating a rhythmic methylation of 'Lys-4' of histone H3 (H3K4me) and this histone modification directs the circadian acetylation at H3K9 and H3K14 allowing the recruitment of CLOCK-BMAL1 to chromatin (By similarity). Also has auto-methylation activity on Cys-3882 in absence of histone H3 substrate (PubMed:24235145). {ECO:0000250|UniProtKB:P55200, ECO:0000269|PubMed:10490642, ECO:0000269|PubMed:12453419, ECO:0000269|PubMed:15960975, ECO:0000269|PubMed:19187761, ECO:0000269|PubMed:19556245, ECO:0000269|PubMed:20010842, ECO:0000269|PubMed:21220120, ECO:0000269|PubMed:24235145, ECO:0000269|PubMed:26886794, ECO:0000305|PubMed:20677832}. |
| Q08050 | FOXM1 | S505 | ochoa | Forkhead box protein M1 (Forkhead-related protein FKHL16) (Hepatocyte nuclear factor 3 forkhead homolog 11) (HFH-11) (HNF-3/fork-head homolog 11) (M-phase phosphoprotein 2) (MPM-2 reactive phosphoprotein 2) (Transcription factor Trident) (Winged-helix factor from INS-1 cells) | Transcription factor regulating the expression of cell cycle genes essential for DNA replication and mitosis (PubMed:19160488, PubMed:20360045). Plays a role in the control of cell proliferation (PubMed:19160488). Also plays a role in DNA break repair, participating in the DNA damage checkpoint response (PubMed:17101782). Promotes transcription of PHB2 (PubMed:33754036). {ECO:0000269|PubMed:17101782, ECO:0000269|PubMed:19160488, ECO:0000269|PubMed:20360045, ECO:0000269|PubMed:33754036}. |
| Q12979 | ABR | S57 | ochoa | Active breakpoint cluster region-related protein | Protein with a unique structure having two opposing regulatory activities toward small GTP-binding proteins. The C-terminus is a GTPase-activating protein domain which stimulates GTP hydrolysis by RAC1, RAC2 and CDC42. Accelerates the intrinsic rate of GTP hydrolysis of RAC1 or CDC42, leading to down-regulation of the active GTP-bound form (PubMed:17116687, PubMed:7479768). The central Dbl homology (DH) domain functions as a guanine nucleotide exchange factor (GEF) that modulates the GTPases CDC42, RHOA and RAC1. Promotes the conversion of CDC42, RHOA and RAC1 from the GDP-bound to the GTP-bound form (PubMed:7479768). Functions as an important negative regulator of neuronal RAC1 activity (By similarity). Regulates macrophage functions such as CSF-1 directed motility and phagocytosis through the modulation of RAC1 activity (By similarity). {ECO:0000250|UniProtKB:Q5SSL4, ECO:0000269|PubMed:17116687, ECO:0000269|PubMed:7479768}. |
| Q13546 | RIPK1 | S335 | psp | Receptor-interacting serine/threonine-protein kinase 1 (EC 2.7.11.1) (Cell death protein RIP) (Receptor-interacting protein 1) (RIP-1) | Serine-threonine kinase which is a key regulator of TNF-mediated apoptosis, necroptosis and inflammatory pathways (PubMed:17703191, PubMed:24144979, PubMed:31827280, PubMed:31827281, PubMed:32657447, PubMed:35831301). Exhibits kinase activity-dependent functions that regulate cell death and kinase-independent scaffold functions regulating inflammatory signaling and cell survival (PubMed:11101870, PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Has kinase-independent scaffold functions: upon binding of TNF to TNFR1, RIPK1 is recruited to the TNF-R1 signaling complex (TNF-RSC also known as complex I) where it acts as a scaffold protein promoting cell survival, in part, by activating the canonical NF-kappa-B pathway (By similarity). Kinase activity is essential to regulate necroptosis and apoptosis, two parallel forms of cell death: upon activation of its protein kinase activity, regulates assembly of two death-inducing complexes, namely complex IIa (RIPK1-FADD-CASP8), which drives apoptosis, and the complex IIb (RIPK1-RIPK3-MLKL), which drives necroptosis (By similarity). RIPK1 is required to limit CASP8-dependent TNFR1-induced apoptosis (By similarity). In normal conditions, RIPK1 acts as an inhibitor of RIPK3-dependent necroptosis, a process mediated by RIPK3 component of complex IIb, which catalyzes phosphorylation of MLKL upon induction by ZBP1 (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Inhibits RIPK3-mediated necroptosis via FADD-mediated recruitment of CASP8, which cleaves RIPK1 and limits TNF-induced necroptosis (PubMed:19524512, PubMed:19524513, PubMed:29440439, PubMed:30988283). Required to inhibit apoptosis and necroptosis during embryonic development: acts by preventing the interaction of TRADD with FADD thereby limiting aberrant activation of CASP8 (By similarity). In addition to apoptosis and necroptosis, also involved in inflammatory response by promoting transcriptional production of pro-inflammatory cytokines, such as interleukin-6 (IL6) (PubMed:31827280, PubMed:31827281). Phosphorylates RIPK3: RIPK1 and RIPK3 undergo reciprocal auto- and trans-phosphorylation (PubMed:19524513). Phosphorylates DAB2IP at 'Ser-728' in a TNF-alpha-dependent manner, and thereby activates the MAP3K5-JNK apoptotic cascade (PubMed:15310755, PubMed:17389591). Required for ZBP1-induced NF-kappa-B activation in response to DNA damage (By similarity). {ECO:0000250|UniProtKB:Q60855, ECO:0000269|PubMed:11101870, ECO:0000269|PubMed:15310755, ECO:0000269|PubMed:17389591, ECO:0000269|PubMed:17703191, ECO:0000269|PubMed:19524512, ECO:0000269|PubMed:19524513, ECO:0000269|PubMed:24144979, ECO:0000269|PubMed:29440439, ECO:0000269|PubMed:30988283, ECO:0000269|PubMed:31827280, ECO:0000269|PubMed:31827281, ECO:0000269|PubMed:32657447, ECO:0000269|PubMed:35831301}. |
| Q13586 | STIM1 | S618 | ochoa|psp | Stromal interaction molecule 1 | Acts as a Ca(2+) sensor that gates two major inward rectifying Ca(2+) channels at the plasma membrane: Ca(2+) release-activated Ca(2+) (CRAC) channels and arachidonate-regulated Ca(2+)-selective (ARC) channels (PubMed:15866891, PubMed:16005298, PubMed:16208375, PubMed:16537481, PubMed:16733527, PubMed:16766533, PubMed:16807233, PubMed:18854159, PubMed:19182790, PubMed:19249086, PubMed:19622606, PubMed:19706554, PubMed:22464749, PubMed:24069340, PubMed:24351972, PubMed:24591628, PubMed:25326555, PubMed:26322679, PubMed:28219928, PubMed:32415068). Plays a role in mediating store-operated Ca(2+) entry (SOCE), a Ca(2+) influx following depletion of intracellular Ca(2+) stores. Upon Ca(2+) depletion, translocates from the endoplasmic reticulum to the plasma membrane where it activates CRAC channel pore-forming subunits ORA1, ORA2 and ORAI3 to generate sustained and oscillatory Ca(2+) entry (PubMed:16208375, PubMed:16537481, PubMed:32415068). Involved in enamel formation (PubMed:24621671). {ECO:0000269|PubMed:15866891, ECO:0000269|PubMed:16005298, ECO:0000269|PubMed:16208375, ECO:0000269|PubMed:16537481, ECO:0000269|PubMed:16733527, ECO:0000269|PubMed:16766533, ECO:0000269|PubMed:16807233, ECO:0000269|PubMed:18854159, ECO:0000269|PubMed:19182790, ECO:0000269|PubMed:19249086, ECO:0000269|PubMed:19622606, ECO:0000269|PubMed:19706554, ECO:0000269|PubMed:22464749, ECO:0000269|PubMed:24069340, ECO:0000269|PubMed:24351972, ECO:0000269|PubMed:24591628, ECO:0000269|PubMed:24621671, ECO:0000269|PubMed:25326555, ECO:0000269|PubMed:26322679, ECO:0000269|PubMed:28219928, ECO:0000269|PubMed:32415068}. |
| Q14157 | UBAP2L | S460 | ochoa | Ubiquitin-associated protein 2-like (Protein NICE-4) (RNA polymerase II degradation factor UBAP2L) | Recruits the ubiquitination machinery to RNA polymerase II for polyubiquitination, removal and degradation, when the transcription-coupled nucleotide excision repair (TC-NER) machinery fails to resolve DNA damage (PubMed:35633597). Plays an important role in the activity of long-term repopulating hematopoietic stem cells (LT-HSCs) (By similarity). Is a regulator of stress granule assembly, required for their efficient formation (PubMed:29395067, PubMed:35977029). Required for proper brain development and neocortex lamination (By similarity). {ECO:0000250|UniProtKB:Q80X50, ECO:0000269|PubMed:29395067, ECO:0000269|PubMed:35633597}. |
| Q14188 | TFDP2 | S42 | ochoa | Transcription factor Dp-2 (E2F dimerization partner 2) | Can stimulate E2F-dependent transcription. Binds DNA cooperatively with E2F family members through the E2 recognition site, 5'-TTTC[CG]CGC-3', found in the promoter region of a number of genes whose products are involved in cell cycle regulation or in DNA replication. The TFDP2:E2F complex functions in the control of cell-cycle progression from G1 to S phase. The E2F1:DP complex appears to mediate both cell proliferation and apoptosis. Blocks adipocyte differentiation by repressing CEBPA binding to its target gene promoters (PubMed:20176812). {ECO:0000305|PubMed:20176812}. |
| Q15942 | ZYX | S288 | ochoa | Zyxin (Zyxin-2) | Adhesion plaque protein. Binds alpha-actinin and the CRP protein. Important for targeting TES and ENA/VASP family members to focal adhesions and for the formation of actin-rich structures. May be a component of a signal transduction pathway that mediates adhesion-stimulated changes in gene expression (By similarity). {ECO:0000250}. |
| Q16204 | CCDC6 | Y356 | ochoa | Coiled-coil domain-containing protein 6 (Papillary thyroid carcinoma-encoded protein) (Protein H4) | None |
| Q16204 | CCDC6 | S395 | ochoa | Coiled-coil domain-containing protein 6 (Papillary thyroid carcinoma-encoded protein) (Protein H4) | None |
| Q3KQU3 | MAP7D1 | S473 | ochoa | MAP7 domain-containing protein 1 (Arginine/proline-rich coiled-coil domain-containing protein 1) (Proline/arginine-rich coiled-coil domain-containing protein 1) | Microtubule-stabilizing protein involved in the control of cell motility and neurite outgrowth. Facilitate microtubule stabilization through the maintenance of acetylated stable microtubules. {ECO:0000250|UniProtKB:A2AJI0}. |
| Q52LW3 | ARHGAP29 | S577 | ochoa | Rho GTPase-activating protein 29 (PTPL1-associated RhoGAP protein 1) (Rho-type GTPase-activating protein 29) | GTPase activator for the Rho-type GTPases by converting them to an inactive GDP-bound state. Has strong activity toward RHOA, and weaker activity toward RAC1 and CDC42. May act as a specific effector of RAP2A to regulate Rho. In concert with RASIP1, suppresses RhoA signaling and dampens ROCK and MYH9 activities in endothelial cells and plays an essential role in blood vessel tubulogenesis. {ECO:0000269|PubMed:15752761, ECO:0000269|PubMed:9305890}. |
| Q5JRA6 | MIA3 | S1706 | ochoa | Transport and Golgi organization protein 1 homolog (TANGO1) (C219-reactive peptide) (D320) (Melanoma inhibitory activity protein 3) | Plays a role in the transport of cargos that are too large to fit into COPII-coated vesicles and require specific mechanisms to be incorporated into membrane-bound carriers and exported from the endoplasmic reticulum. This protein is required for collagen VII (COL7A1) secretion by loading COL7A1 into transport carriers. It may participate in cargo loading of COL7A1 at endoplasmic reticulum exit sites by binding to COPII coat subunits Sec23/24 and guiding SH3-bound COL7A1 into a growing carrier. Does not play a role in global protein secretion and is apparently specific to COL7A1 cargo loading. However, it may participate in secretion of other proteins in cells that do not secrete COL7A1. It is also specifically required for the secretion of lipoproteins by participating in their export from the endoplasmic reticulum (PubMed:19269366, PubMed:27138255). Required for correct assembly of COPII coat components at endoplasmic reticulum exit sites (ERES) and for the localization of SEC16A and membrane-bound ER-resident complexes consisting of MIA2 and PREB/SEC12 to ERES (PubMed:28442536). {ECO:0000269|PubMed:19269366, ECO:0000269|PubMed:27138255, ECO:0000269|PubMed:28442536}. |
| Q5SNT2 | TMEM201 | S561 | ochoa | Transmembrane protein 201 (Spindle-associated membrane protein 1) | Critical regulator of angiogenesis and endothelial cell (EC) migration (PubMed:35311970). Promotes the migration of endothelial cells, which is essential for angiogenesis (PubMed:35311970). Interacts with the linker of nucleoskeleton and cytoskeleton (LINC) complex, which plays a vital role in connecting the cell's cytoskeleton to the nuclear envelope (PubMed:35311970). This interaction is essential for maintaining cellular structure and facilitating the movement of endothelial cells, which is critical for proper vascular development (PubMed:35311970). Involved in nuclear movement during fibroblast polarization and migration (By similarity). Overexpression can recruit Ran GTPase to the nuclear periphery (PubMed:27541860). {ECO:0000250|UniProtKB:A2A8U2, ECO:0000269|PubMed:35311970, ECO:0000305|PubMed:27541860}.; FUNCTION: [Isoform 2]: May define a distinct membrane domain in the vicinity of the mitotic spindle (PubMed:19494128). Involved in the organization of the nuclear envelope implicating EMD, SUN1 and A-type lamina (PubMed:21610090). {ECO:0000269|PubMed:19494128, ECO:0000269|PubMed:21610090}. |
| Q5SW79 | CEP170 | S1216 | ochoa | Centrosomal protein of 170 kDa (Cep170) (KARP-1-binding protein) (KARP1-binding protein) | Plays a role in microtubule organization (PubMed:15616186). Required for centriole subdistal appendage assembly (PubMed:28422092). {ECO:0000269|PubMed:15616186, ECO:0000269|PubMed:28422092}. |
| Q5T200 | ZC3H13 | S329 | ochoa | Zinc finger CCCH domain-containing protein 13 | Associated component of the WMM complex, a complex that mediates N6-methyladenosine (m6A) methylation of RNAs, a modification that plays a role in the efficiency of mRNA splicing and RNA processing (PubMed:29507755). Acts as a key regulator of m6A methylation by promoting m6A methylation of mRNAs at the 3'-UTR (By similarity). Controls embryonic stem cells (ESCs) pluripotency via its role in m6A methylation (By similarity). In the WMM complex, anchors component of the MACOM subcomplex in the nucleus (By similarity). Also required for bridging WTAP to the RNA-binding component RBM15 (RBM15 or RBM15B) (By similarity). {ECO:0000250|UniProtKB:E9Q784}. |
| Q6GQQ9 | OTUD7B | S464 | ochoa | OTU domain-containing protein 7B (EC 3.4.19.12) (Cellular zinc finger anti-NF-kappa-B protein) (Cezanne) (Zinc finger A20 domain-containing protein 1) (Zinc finger protein Cezanne) | Negative regulator of the non-canonical NF-kappa-B pathway that acts by mediating deubiquitination of TRAF3, an inhibitor of the NF-kappa-B pathway, thereby acting as a negative regulator of B-cell responses (PubMed:18178551). In response to non-canonical NF-kappa-B stimuli, deubiquitinates 'Lys-48'-linked polyubiquitin chains of TRAF3, preventing TRAF3 proteolysis and over-activation of non-canonical NF-kappa-B (By similarity). Negatively regulates mucosal immunity against infections (By similarity). Deubiquitinates ZAP70, and thereby regulates T cell receptor (TCR) signaling that leads to the activation of NF-kappa-B (PubMed:26903241). Plays a role in T cell homeostasis and is required for normal T cell responses, including production of IFNG and IL2 (By similarity). Mediates deubiquitination of EGFR (PubMed:22179831). Has deubiquitinating activity toward 'Lys-11', 'Lys-48' and 'Lys-63'-linked polyubiquitin chains (PubMed:11463333, PubMed:20622874, PubMed:23827681, PubMed:27732584). Has a much higher catalytic rate with 'Lys-11'-linked polyubiquitin chains (in vitro); however the physiological significance of these data are unsure (PubMed:27732584). Hydrolyzes both linear and branched forms of polyubiquitin (PubMed:12682062). Acts as a regulator of mTORC1 and mTORC2 assembly by mediating 'Lys-63'-linked deubiquitination of MLST8, thereby promoting assembly of the mTORC2 complex, while inibiting formation of the mTORC1 complex (PubMed:28489822). {ECO:0000250|UniProtKB:B2RUR8, ECO:0000269|PubMed:11463333, ECO:0000269|PubMed:12682062, ECO:0000269|PubMed:18178551, ECO:0000269|PubMed:20622874, ECO:0000269|PubMed:22179831, ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:26903241, ECO:0000269|PubMed:27732584, ECO:0000269|PubMed:28489822}. |
| Q6P1L5 | FAM117B | S414 | ochoa | Protein FAM117B (Amyotrophic lateral sclerosis 2 chromosomal region candidate gene 13 protein) | None |
| Q6PGQ7 | BORA | S308 | ochoa | Protein aurora borealis (HsBora) | Required for the activation of AURKA at the onset of mitosis. {ECO:0000269|PubMed:16890155}. |
| Q6VN20 | RANBP10 | Y362 | ochoa | Ran-binding protein 10 (RanBP10) | May act as an adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but does not affect estrogen-induced transactivation (PubMed:18222118). Acts as a guanine nucleotide exchange factor (GEF) for RAN GTPase. May play an essential role in hemostasis and in maintaining microtubule dynamics with respect to both platelet shape and function (By similarity). {ECO:0000250|UniProtKB:Q6VN19, ECO:0000269|PubMed:18222118, ECO:0000269|PubMed:29911972, ECO:0000305}. |
| Q6VN20 | RANBP10 | S369 | ochoa | Ran-binding protein 10 (RanBP10) | May act as an adapter protein to couple membrane receptors to intracellular signaling pathways (Probable). Core component of the CTLH E3 ubiquitin-protein ligase complex that selectively accepts ubiquitin from UBE2H and mediates ubiquitination and subsequent proteasomal degradation of the transcription factor HBP1 (PubMed:29911972). Enhances dihydrotestosterone-induced transactivation activity of AR, as well as dexamethasone-induced transactivation activity of NR3C1, but does not affect estrogen-induced transactivation (PubMed:18222118). Acts as a guanine nucleotide exchange factor (GEF) for RAN GTPase. May play an essential role in hemostasis and in maintaining microtubule dynamics with respect to both platelet shape and function (By similarity). {ECO:0000250|UniProtKB:Q6VN19, ECO:0000269|PubMed:18222118, ECO:0000269|PubMed:29911972, ECO:0000305}. |
| Q6VY07 | PACS1 | S774 | ochoa | Phosphofurin acidic cluster sorting protein 1 (PACS-1) | Coat protein that is involved in the localization of trans-Golgi network (TGN) membrane proteins that contain acidic cluster sorting motifs. Controls the endosome-to-Golgi trafficking of furin and mannose-6-phosphate receptor by connecting the acidic-cluster-containing cytoplasmic domain of these molecules with the adapter-protein complex-1 (AP-1) of endosomal clathrin-coated membrane pits. Involved in HIV-1 nef-mediated removal of MHC-I from the cell surface to the TGN. Required for normal ER Ca2+ handling in lymphocytes. Together with WDR37, it plays an essential role in lymphocyte development, quiescence and survival. Required for stabilizing peripheral lymphocyte populations (By similarity). {ECO:0000250|UniProtKB:Q8K212, ECO:0000269|PubMed:11331585, ECO:0000269|PubMed:15692563}. |
| Q7Z5J4 | RAI1 | S1126 | ochoa | Retinoic acid-induced protein 1 | Transcriptional regulator of the circadian clock components: CLOCK, BMAL1, BMAL2, PER1/3, CRY1/2, NR1D1/2 and RORA/C. Positively regulates the transcriptional activity of CLOCK a core component of the circadian clock. Regulates transcription through chromatin remodeling by interacting with other proteins in chromatin as well as proteins in the basic transcriptional machinery. May be important for embryonic and postnatal development. May be involved in neuronal differentiation. {ECO:0000269|PubMed:22578325}. |
| Q7Z5L9 | IRF2BP2 | S399 | ochoa | Interferon regulatory factor 2-binding protein 2 (IRF-2-binding protein 2) (IRF-2BP2) | Acts as a transcriptional corepressor in a IRF2-dependent manner; this repression is not mediated by histone deacetylase activities (PubMed:12799427). Represses the NFAT1-dependent transactivation of NFAT-responsive promoters (PubMed:21576369). Acts as a coactivator of VEGFA expression in cardiac and skeletal muscles (PubMed:20702774). Plays a role in immature B-cell differentiation (PubMed:27016798). {ECO:0000269|PubMed:12799427, ECO:0000269|PubMed:20702774, ECO:0000269|PubMed:21576369, ECO:0000269|PubMed:27016798}. |
| Q7Z5L9 | IRF2BP2 | S406 | ochoa | Interferon regulatory factor 2-binding protein 2 (IRF-2-binding protein 2) (IRF-2BP2) | Acts as a transcriptional corepressor in a IRF2-dependent manner; this repression is not mediated by histone deacetylase activities (PubMed:12799427). Represses the NFAT1-dependent transactivation of NFAT-responsive promoters (PubMed:21576369). Acts as a coactivator of VEGFA expression in cardiac and skeletal muscles (PubMed:20702774). Plays a role in immature B-cell differentiation (PubMed:27016798). {ECO:0000269|PubMed:12799427, ECO:0000269|PubMed:20702774, ECO:0000269|PubMed:21576369, ECO:0000269|PubMed:27016798}. |
| Q86VP3 | PACS2 | S691 | ochoa | Phosphofurin acidic cluster sorting protein 2 (PACS-2) (PACS1-like protein) | Multifunctional sorting protein that controls the endoplasmic reticulum (ER)-mitochondria communication, including the apposition of mitochondria with the ER and ER homeostasis. In addition, in response to apoptotic inducer, translocates BIB to mitochondria, which initiates a sequence of events including the formation of mitochondrial truncated BID, the release of cytochrome c, the activation of caspase-3 thereby causing cell death. May also be involved in ion channel trafficking, directing acidic cluster-containing ion channels to distinct subcellular compartments. {ECO:0000269|PubMed:15692563, ECO:0000269|PubMed:15692567}. |
| Q86VP3 | PACS2 | S706 | ochoa | Phosphofurin acidic cluster sorting protein 2 (PACS-2) (PACS1-like protein) | Multifunctional sorting protein that controls the endoplasmic reticulum (ER)-mitochondria communication, including the apposition of mitochondria with the ER and ER homeostasis. In addition, in response to apoptotic inducer, translocates BIB to mitochondria, which initiates a sequence of events including the formation of mitochondrial truncated BID, the release of cytochrome c, the activation of caspase-3 thereby causing cell death. May also be involved in ion channel trafficking, directing acidic cluster-containing ion channels to distinct subcellular compartments. {ECO:0000269|PubMed:15692563, ECO:0000269|PubMed:15692567}. |
| Q86XP3 | DDX42 | S758 | ochoa | ATP-dependent RNA helicase DDX42 (EC 3.6.4.13) (DEAD box protein 42) (RNA helicase-like protein) (RHELP) (RNA helicase-related protein) (RNAHP) (SF3b DEAD box protein) (Splicing factor 3B-associated 125 kDa protein) (SF3b125) | ATP-dependent RNA helicase that binds to partially double-stranded RNAs (dsRNAs) in order to unwind RNA secondary structures (PubMed:16397294). Unwinding is promoted in the presence of single-strand binding proteins (PubMed:16397294). Also mediates RNA duplex formation thereby displacing the single-strand RNA binding protein (PubMed:16397294). ATP and ADP modulate its activity: ATP binding and hydrolysis by DDX42 triggers RNA strand separation, whereas the ADP-bound form of the protein triggers annealing of complementary RNA strands (PubMed:16397294). Required for assembly of the 17S U2 SnRNP complex of the spliceosome, a large ribonucleoprotein complex that removes introns from transcribed pre-mRNAs: DDX42 associates transiently with the SF3B subcomplex of the 17S U2 SnRNP complex and is released after fulfilling its role in the assembly of 17S U2 SnRNP (PubMed:12234937, PubMed:36797247). Involved in the survival of cells by interacting with TP53BP2 and thereby counteracting the apoptosis-stimulating activity of TP53BP2 (PubMed:19377511). Relocalizes TP53BP2 to the cytoplasm (PubMed:19377511). {ECO:0000269|PubMed:12234937, ECO:0000269|PubMed:16397294, ECO:0000269|PubMed:19377511, ECO:0000269|PubMed:36797247}. |
| Q8IV63 | VRK3 | T119 | ochoa | Serine/threonine-protein kinase VRK3 (EC 2.7.11.22) (Vaccinia-related kinase 3) | Plays a role in the regulation of the cell cycle by phosphorylating the nuclear envelope protein barrier-to-autointegration factor/BAF that is required for disassembly and reassembly, respectively, of the nuclear envelope during mitosis (PubMed:25899223). Under normal physiological conditions, negatively regulates ERK activity along with VHR/DUSP3 phosphatase in the nucleus, causing timely and transient action of ERK. Stress conditions activate CDK5 which phosphorylates VRK3 to increase VHR phosphatase activity and suppress prolonged ERK activation that causes cell death (PubMed:27346674). For example, upon glutamate induction, promotes nuclear localization of HSP70/HSPA1A to inhibit ERK activation via VHR/DUSP3 phosphatase (PubMed:27941812). {ECO:0000250|UniProtKB:Q8K3G5, ECO:0000269|PubMed:14645249, ECO:0000269|PubMed:19141289, ECO:0000269|PubMed:25899223, ECO:0000269|PubMed:27346674, ECO:0000269|PubMed:27941812}. |
| Q8IY92 | SLX4 | S1333 | ochoa | Structure-specific endonuclease subunit SLX4 (BTB/POZ domain-containing protein 12) | Regulatory subunit that interacts with and increases the activity of different structure-specific endonucleases. Has several distinct roles in protecting genome stability by resolving diverse forms of deleterious DNA structures originating from replication and recombination intermediates and from DNA damage. Component of the SLX1-SLX4 structure-specific endonuclease that resolves DNA secondary structures generated during DNA repair and recombination. Has endonuclease activity towards branched DNA substrates, introducing single-strand cuts in duplex DNA close to junctions with ss-DNA. Has a preference for 5'-flap structures, and promotes symmetrical cleavage of static and migrating Holliday junctions (HJs). Resolves HJs by generating two pairs of ligatable, nicked duplex products. Interacts with the structure-specific ERCC4-ERCC1 endonuclease and promotes the cleavage of bubble structures. Interacts with the structure-specific MUS81-EME1 endonuclease and promotes the cleavage of 3'-flap and replication fork-like structures. SLX4 is required for recovery from alkylation-induced DNA damage and is involved in the resolution of DNA double-strand breaks. {ECO:0000269|PubMed:19595721, ECO:0000269|PubMed:19595722, ECO:0000269|PubMed:19596235, ECO:0000269|PubMed:19596236}. |
| Q8IZW8 | TNS4 | S368 | ochoa | Tensin-4 (C-terminal tensin-like protein) | Promotes EGF-induced cell migration by displacing tensin TNS3 from the cytoplasmic tail of integrin ITGB1 which results in dissociation of TNS3 from focal adhesions, disassembly of actin stress fibers and initiation of cell migration (PubMed:17643115). Suppresses ligand-induced degradation of EGFR by reducing EGFR ubiquitination in the presence of EGF (PubMed:23774213). Increases MET protein stability by inhibiting MET endocytosis and subsequent lysosomal degradation which leads to increased cell survival, proliferation and migration (PubMed:24814316). {ECO:0000269|PubMed:17643115, ECO:0000269|PubMed:23774213, ECO:0000269|PubMed:24814316}. |
| Q8NFH5 | NUP35 | S121 | ochoa | Nucleoporin NUP35 (35 kDa nucleoporin) (Mitotic phosphoprotein 44) (MP-44) (Nuclear pore complex protein Nup53) (Nucleoporin NUP53) | Functions as a component of the nuclear pore complex (NPC). NPC components, collectively referred to as nucleoporins (NUPs), can play the role of both NPC structural components and of docking or interaction partners for transiently associated nuclear transport factors. May play a role in the association of MAD1 with the NPC. {ECO:0000269|PubMed:15703211}. |
| Q8NHG8 | ZNRF2 | S120 | ochoa | E3 ubiquitin-protein ligase ZNRF2 (EC 2.3.2.27) (Protein Ells2) (RING finger protein 202) (RING-type E3 ubiquitin transferase ZNRF2) (Zinc/RING finger protein 2) | E3 ubiquitin-protein ligase that plays a role in the establishment and maintenance of neuronal transmission and plasticity. Ubiquitinates the Na(+)/K(+) ATPase alpha-1 subunit/ATP1A1 and thereby influences its endocytosis and/or degradation (PubMed:22797923). Acts also as a positive regulator of mTORC1 activation by amino acids, which functions upstream of the V-ATPase and of Rag-GTPases (PubMed:27244671). In turn, phosphorylation by mTOR leads to its inhibition via targeting to the cytosol allowing a self-regulating feedback mechanism (PubMed:27244671). {ECO:0000269|PubMed:14561866, ECO:0000269|PubMed:22797923, ECO:0000269|PubMed:27244671}. |
| Q8WWI1 | LMO7 | S1009 | ochoa | LIM domain only protein 7 (LMO-7) (F-box only protein 20) (LOMP) | None |
| Q92738 | USP6NL | Y802 | ochoa | USP6 N-terminal-like protein (Related to the N-terminus of tre) (RN-tre) | Acts as a GTPase-activating protein for RAB5A and RAB43. Involved in receptor trafficking. In complex with EPS8 inhibits internalization of EGFR. Involved in retrograde transport from the endocytic pathway to the Golgi apparatus. Involved in the transport of Shiga toxin from early and recycling endosomes to the trans-Golgi network. Required for structural integrity of the Golgi complex. {ECO:0000269|PubMed:11099046, ECO:0000269|PubMed:17562788, ECO:0000269|PubMed:17684057}. |
| Q969V6 | MRTFA | S124 | ochoa | Myocardin-related transcription factor A (MRTF-A) (MKL/myocardin-like protein 1) (Megakaryoblastic leukemia 1 protein) (Megakaryocytic acute leukemia protein) | Transcription coactivator that associates with the serum response factor (SRF) transcription factor to control expression of genes regulating the cytoskeleton during development, morphogenesis and cell migration (PubMed:26224645). The SRF-MRTFA complex activity responds to Rho GTPase-induced changes in cellular globular actin (G-actin) concentration, thereby coupling cytoskeletal gene expression to cytoskeletal dynamics. MRTFA binds G-actin via its RPEL repeats, regulating activity of the MRTFA-SRF complex. Activity is also regulated by filamentous actin (F-actin) in the nucleus. {ECO:0000250|UniProtKB:Q8K4J6, ECO:0000269|PubMed:26224645}. |
| Q96AY4 | TTC28 | S32 | ochoa | Tetratricopeptide repeat protein 28 (TPR repeat protein 28) (TPR repeat-containing big gene cloned at Keio) | During mitosis, may be involved in the condensation of spindle midzone microtubules, leading to the formation of midbody. {ECO:0000269|PubMed:23036704}. |
| Q96E39 | RBMXL1 | S284 | ochoa | RNA binding motif protein, X-linked-like-1 (Heterogeneous nuclear ribonucleoprotein G-like 1) | RNA-binding protein which may be involved in pre-mRNA splicing. {ECO:0000250}. |
| Q96E39 | RBMXL1 | S291 | ochoa | RNA binding motif protein, X-linked-like-1 (Heterogeneous nuclear ribonucleoprotein G-like 1) | RNA-binding protein which may be involved in pre-mRNA splicing. {ECO:0000250}. |
| Q96F24 | NRBF2 | S120 | ochoa|psp | Nuclear receptor-binding factor 2 (NRBF-2) (Comodulator of PPAR and RXR) | May modulate transcriptional activation by target nuclear receptors. Can act as transcriptional activator (in vitro). {ECO:0000269|PubMed:15610520}.; FUNCTION: Involved in starvation-induced autophagy probably by its association with PI3K complex I (PI3KC3-C1). However, effects has been described variably. Involved in the induction of starvation-induced autophagy (PubMed:24785657). Stabilizes PI3KC3-C1 assembly and enhances ATG14-linked lipid kinase activity of PIK3C3 (By similarity). Proposed to negatively regulate basal and starvation-induced autophagy and to inhibit PIK3C3 activity by modulating interactions in PI3KC3-C1 (PubMed:25086043). May be involved in autophagosome biogenesis (PubMed:25086043). May play a role in neural progenitor cell survival during differentiation (By similarity). {ECO:0000250|UniProtKB:Q8VCQ3, ECO:0000269|PubMed:24785657, ECO:0000269|PubMed:25086043}. |
| Q96JM3 | CHAMP1 | S376 | ochoa | Chromosome alignment-maintaining phosphoprotein 1 (Zinc finger protein 828) | Required for proper alignment of chromosomes at metaphase and their accurate segregation during mitosis. Involved in the maintenance of spindle microtubules attachment to the kinetochore during sister chromatid biorientation. May recruit CENPE and CENPF to the kinetochore. {ECO:0000269|PubMed:21063390}. |
| Q96JM3 | CHAMP1 | S483 | ochoa | Chromosome alignment-maintaining phosphoprotein 1 (Zinc finger protein 828) | Required for proper alignment of chromosomes at metaphase and their accurate segregation during mitosis. Involved in the maintenance of spindle microtubules attachment to the kinetochore during sister chromatid biorientation. May recruit CENPE and CENPF to the kinetochore. {ECO:0000269|PubMed:21063390}. |
| Q99081 | TCF12 | S83 | ochoa | Transcription factor 12 (TCF-12) (Class B basic helix-loop-helix protein 20) (bHLHb20) (DNA-binding protein HTF4) (E-box-binding protein) (Transcription factor HTF-4) | Transcriptional regulator. Involved in the initiation of neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3') (By similarity). May be involved in the functional network that regulates the development of the GnRH axis (PubMed:32620954). {ECO:0000250|UniProtKB:Q61286, ECO:0000269|PubMed:32620954}. |
| Q99081 | TCF12 | S366 | ochoa | Transcription factor 12 (TCF-12) (Class B basic helix-loop-helix protein 20) (bHLHb20) (DNA-binding protein HTF4) (E-box-binding protein) (Transcription factor HTF-4) | Transcriptional regulator. Involved in the initiation of neuronal differentiation. Activates transcription by binding to the E box (5'-CANNTG-3') (By similarity). May be involved in the functional network that regulates the development of the GnRH axis (PubMed:32620954). {ECO:0000250|UniProtKB:Q61286, ECO:0000269|PubMed:32620954}. |
| Q99569 | PKP4 | S247 | ochoa | Plakophilin-4 (p0071) | Plays a role as a regulator of Rho activity during cytokinesis. May play a role in junctional plaques. {ECO:0000269|PubMed:17115030}. |
| Q99704 | DOK1 | S443 | psp | Docking protein 1 (Downstream of tyrosine kinase 1) (p62(dok)) (pp62) | DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK1 appears to be a negative regulator of the insulin signaling pathway. Modulates integrin activation by competing with talin for the same binding site on ITGB3. {ECO:0000269|PubMed:18156175}. |
| Q99704 | DOK1 | S450 | ochoa|psp | Docking protein 1 (Downstream of tyrosine kinase 1) (p62(dok)) (pp62) | DOK proteins are enzymatically inert adaptor or scaffolding proteins. They provide a docking platform for the assembly of multimolecular signaling complexes. DOK1 appears to be a negative regulator of the insulin signaling pathway. Modulates integrin activation by competing with talin for the same binding site on ITGB3. {ECO:0000269|PubMed:18156175}. |
| Q9BR39 | JPH2 | S469 | ochoa | Junctophilin-2 (JP-2) (Junctophilin type 2) [Cleaved into: Junctophilin-2 N-terminal fragment (JP2NT)] | [Junctophilin-2]: Membrane-binding protein that provides a structural bridge between the plasma membrane and the sarcoplasmic reticulum and is required for normal excitation-contraction coupling in cardiomyocytes (PubMed:20095964). Provides a structural foundation for functional cross-talk between the cell surface and intracellular Ca(2+) release channels by maintaining the 12-15 nm gap between the sarcolemma and the sarcoplasmic reticulum membranes in the cardiac dyads (By similarity). Necessary for proper intracellular Ca(2+) signaling in cardiac myocytes via its involvement in ryanodine receptor-mediated calcium ion release (By similarity). Contributes to the construction of skeletal muscle triad junctions (By similarity). {ECO:0000250|UniProtKB:Q9ET78, ECO:0000269|PubMed:20095964}.; FUNCTION: [Junctophilin-2 N-terminal fragment]: Transcription repressor required to safeguard against the deleterious effects of cardiac stress. Generated following cleavage of the Junctophilin-2 chain by calpain in response to cardiac stress in cardiomyocytes. Following cleavage and release from the membrane, translocates to the nucleus, binds DNA and represses expression of genes implicated in cell growth and differentiation, hypertrophy, inflammation and fibrosis. Modifies the transcription profile and thereby attenuates pathological remodeling in response to cardiac stress. Probably acts by competing with MEF2 transcription factors and TATA-binding proteins. {ECO:0000250|UniProtKB:Q9ET78}. |
| Q9C0B0 | UNK | S378 | ochoa|psp | RING finger protein unkempt homolog (Zinc finger CCCH domain-containing protein 5) | Sequence-specific RNA-binding protein which plays an important role in the establishment and maintenance of the early morphology of cortical neurons during embryonic development. Acts as a translation repressor and controls a translationally regulated cell morphology program to ensure proper structuring of the nervous system. Translational control depends on recognition of its binding element within target mRNAs which consists of a mandatory UAG trimer upstream of a U/A-rich motif. Associated with polysomes (PubMed:25737280). {ECO:0000269|PubMed:25737280}. |
| Q9C0D5 | TANC1 | S1663 | ochoa | Protein TANC1 (Tetratricopeptide repeat, ankyrin repeat and coiled-coil domain-containing protein 1) | May be a scaffold component in the postsynaptic density. {ECO:0000250}. |
| Q9H1A4 | ANAPC1 | S522 | ochoa | Anaphase-promoting complex subunit 1 (APC1) (Cyclosome subunit 1) (Mitotic checkpoint regulator) (Testis-specific gene 24 protein) | Component of the anaphase promoting complex/cyclosome (APC/C), a cell cycle-regulated E3 ubiquitin ligase that controls progression through mitosis and the G1 phase of the cell cycle (PubMed:18485873). The APC/C complex acts by mediating ubiquitination and subsequent degradation of target proteins: it mainly mediates the formation of 'Lys-11'-linked polyubiquitin chains and, to a lower extent, the formation of 'Lys-48'- and 'Lys-63'-linked polyubiquitin chains (PubMed:18485873). The APC/C complex catalyzes assembly of branched 'Lys-11'-/'Lys-48'-linked branched ubiquitin chains on target proteins (PubMed:29033132). {ECO:0000269|PubMed:18485873, ECO:0000269|PubMed:29033132}. |
| Q9UBW5 | BIN2 | S277 | ochoa | Bridging integrator 2 (Breast cancer-associated protein 1) | Promotes cell motility and migration, probably via its interaction with the cell membrane and with podosome proteins that mediate interaction with the cytoskeleton. Modulates membrane curvature and mediates membrane tubulation. Plays a role in podosome formation. Inhibits phagocytosis. {ECO:0000269|PubMed:23285027}. |
| Q9UBW5 | BIN2 | S429 | ochoa | Bridging integrator 2 (Breast cancer-associated protein 1) | Promotes cell motility and migration, probably via its interaction with the cell membrane and with podosome proteins that mediate interaction with the cytoskeleton. Modulates membrane curvature and mediates membrane tubulation. Plays a role in podosome formation. Inhibits phagocytosis. {ECO:0000269|PubMed:23285027}. |
| Q9UBW5 | BIN2 | S440 | ochoa | Bridging integrator 2 (Breast cancer-associated protein 1) | Promotes cell motility and migration, probably via its interaction with the cell membrane and with podosome proteins that mediate interaction with the cytoskeleton. Modulates membrane curvature and mediates membrane tubulation. Plays a role in podosome formation. Inhibits phagocytosis. {ECO:0000269|PubMed:23285027}. |
| Q9UBW5 | BIN2 | S451 | ochoa | Bridging integrator 2 (Breast cancer-associated protein 1) | Promotes cell motility and migration, probably via its interaction with the cell membrane and with podosome proteins that mediate interaction with the cytoskeleton. Modulates membrane curvature and mediates membrane tubulation. Plays a role in podosome formation. Inhibits phagocytosis. {ECO:0000269|PubMed:23285027}. |
| Q9UHF7 | TRPS1 | S1066 | ochoa | Zinc finger transcription factor Trps1 (Tricho-rhino-phalangeal syndrome type I protein) (Zinc finger protein GC79) | Transcriptional repressor. Binds specifically to GATA sequences and represses expression of GATA-regulated genes at selected sites and stages in vertebrate development. Regulates chondrocyte proliferation and differentiation. Executes multiple functions in proliferating chondrocytes, expanding the region of distal chondrocytes, activating proliferation in columnar cells and supporting the differentiation of columnar into hypertrophic chondrocytes. {ECO:0000269|PubMed:12885770, ECO:0000269|PubMed:17391059}. |
| Q9UKV3 | ACIN1 | Y668 | ochoa | Apoptotic chromatin condensation inducer in the nucleus (Acinus) | Auxiliary component of the splicing-dependent multiprotein exon junction complex (EJC) deposited at splice junction on mRNAs. The EJC is a dynamic structure consisting of core proteins and several peripheral nuclear and cytoplasmic associated factors that join the complex only transiently either during EJC assembly or during subsequent mRNA metabolism. Component of the ASAP complexes which bind RNA in a sequence-independent manner and are proposed to be recruited to the EJC prior to or during the splicing process and to regulate specific excision of introns in specific transcription subsets; ACIN1 confers RNA-binding to the complex. The ASAP complex can inhibit RNA processing during in vitro splicing reactions. The ASAP complex promotes apoptosis and is disassembled after induction of apoptosis. Involved in the splicing modulation of BCL2L1/Bcl-X (and probably other apoptotic genes); specifically inhibits formation of proapoptotic isoforms such as Bcl-X(S); the activity is different from the established EJC assembly and function. Induces apoptotic chromatin condensation after activation by CASP3. Regulates cyclin A1, but not cyclin A2, expression in leukemia cells. {ECO:0000269|PubMed:10490026, ECO:0000269|PubMed:12665594, ECO:0000269|PubMed:18559500, ECO:0000269|PubMed:22203037, ECO:0000269|PubMed:22388736}. |
| Q9ULH1 | ASAP1 | S823 | ochoa | Arf-GAP with SH3 domain, ANK repeat and PH domain-containing protein 1 (130 kDa phosphatidylinositol 4,5-bisphosphate-dependent ARF1 GTPase-activating protein) (ADP-ribosylation factor-directed GTPase-activating protein 1) (ARF GTPase-activating protein 1) (Development and differentiation-enhancing factor 1) (DEF-1) (Differentiation-enhancing factor 1) (PIP2-dependent ARF1 GAP) | Possesses phosphatidylinositol 4,5-bisphosphate-dependent GTPase-activating protein activity for ARF1 (ADP ribosylation factor 1) and ARF5 and a lesser activity towards ARF6. May coordinate membrane trafficking with cell growth or actin cytoskeleton remodeling by binding to both SRC and PIP2. May function as a signal transduction protein involved in the differentiation of fibroblasts into adipocytes and possibly other cell types. Part of the ciliary targeting complex containing Rab11, ASAP1, Rabin8/RAB3IP, RAB11FIP3 and ARF4, which direct preciliary vesicle trafficking to mother centriole and ciliogenesis initiation (PubMed:25673879). {ECO:0000250, ECO:0000269|PubMed:20393563, ECO:0000269|PubMed:25673879}. |
| Q9UPA5 | BSN | S1481 | ochoa | Protein bassoon (Zinc finger protein 231) | Scaffold protein of the presynaptic cytomatrix at the active zone (CAZ) which is the place in the synapse where neurotransmitter is released (PubMed:12812759). After synthesis, participates in the formation of Golgi-derived membranous organelles termed Piccolo-Bassoon transport vesicles (PTVs) that are transported along axons to sites of nascent synaptic contacts (PubMed:19380881). At the presynaptic active zone, regulates the spatial organization of synaptic vesicle cluster, the protein complexes that execute membrane fusion and compensatory endocytosis (By similarity). Also functions in processes other than assembly such as the regulation of specific presynaptic protein ubiquitination by interacting with SIAH1 or the regulation of presynaptic autophagy by associating with ATG5 (By similarity). Also mediates synapse to nucleus communication leading to reconfiguration of gene expression by associating with the transcriptional corepressor CTBP1 and by subsequently reducing the size of its pool available for nuclear import (By similarity). Inhibits the activity of the proportion of DAO enzyme that localizes to the presynaptic active zone, which may modulate synaptic transmission (By similarity). {ECO:0000250|UniProtKB:O35078, ECO:0000250|UniProtKB:O88778, ECO:0000269|PubMed:12812759, ECO:0000269|PubMed:19380881}. |
| Q9UQ35 | SRRM2 | S887 | ochoa | Serine/arginine repetitive matrix protein 2 (300 kDa nuclear matrix antigen) (Serine/arginine-rich splicing factor-related nuclear matrix protein of 300 kDa) (SR-related nuclear matrix protein of 300 kDa) (Ser/Arg-related nuclear matrix protein of 300 kDa) (Splicing coactivator subunit SRm300) (Tax-responsive enhancer element-binding protein 803) (TaxREB803) | Required for pre-mRNA splicing as component of the spliceosome. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). {ECO:0000269|PubMed:19854871, ECO:0000269|PubMed:28076346, ECO:0000269|PubMed:28502770, ECO:0000269|PubMed:29301961, ECO:0000269|PubMed:29360106, ECO:0000269|PubMed:29361316, ECO:0000269|PubMed:30705154, ECO:0000269|PubMed:9531537, ECO:0000305|PubMed:33509932}. |
| Q9UQ35 | SRRM2 | S1021 | ochoa | Serine/arginine repetitive matrix protein 2 (300 kDa nuclear matrix antigen) (Serine/arginine-rich splicing factor-related nuclear matrix protein of 300 kDa) (SR-related nuclear matrix protein of 300 kDa) (Ser/Arg-related nuclear matrix protein of 300 kDa) (Splicing coactivator subunit SRm300) (Tax-responsive enhancer element-binding protein 803) (TaxREB803) | Required for pre-mRNA splicing as component of the spliceosome. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). {ECO:0000269|PubMed:19854871, ECO:0000269|PubMed:28076346, ECO:0000269|PubMed:28502770, ECO:0000269|PubMed:29301961, ECO:0000269|PubMed:29360106, ECO:0000269|PubMed:29361316, ECO:0000269|PubMed:30705154, ECO:0000269|PubMed:9531537, ECO:0000305|PubMed:33509932}. |
| Q9UQ35 | SRRM2 | S1455 | ochoa | Serine/arginine repetitive matrix protein 2 (300 kDa nuclear matrix antigen) (Serine/arginine-rich splicing factor-related nuclear matrix protein of 300 kDa) (SR-related nuclear matrix protein of 300 kDa) (Ser/Arg-related nuclear matrix protein of 300 kDa) (Splicing coactivator subunit SRm300) (Tax-responsive enhancer element-binding protein 803) (TaxREB803) | Required for pre-mRNA splicing as component of the spliceosome. As a component of the minor spliceosome, involved in the splicing of U12-type introns in pre-mRNAs (Probable). {ECO:0000269|PubMed:19854871, ECO:0000269|PubMed:28076346, ECO:0000269|PubMed:28502770, ECO:0000269|PubMed:29301961, ECO:0000269|PubMed:29360106, ECO:0000269|PubMed:29361316, ECO:0000269|PubMed:30705154, ECO:0000269|PubMed:9531537, ECO:0000305|PubMed:33509932}. |
| Q9Y2H5 | PLEKHA6 | S459 | ochoa | Pleckstrin homology domain-containing family A member 6 (PH domain-containing family A member 6) (Phosphoinositol 3-phosphate-binding protein 3) (PEPP-3) | None |
| Q15349 | RPS6KA2 | S381 | Sugiyama | Ribosomal protein S6 kinase alpha-2 (S6K-alpha-2) (EC 2.7.11.1) (90 kDa ribosomal protein S6 kinase 2) (p90-RSK 2) (p90RSK2) (MAP kinase-activated protein kinase 1c) (MAPK-activated protein kinase 1c) (MAPKAP kinase 1c) (MAPKAPK-1c) (Ribosomal S6 kinase 3) (RSK-3) (pp90RSK3) | Serine/threonine-protein kinase that acts downstream of ERK (MAPK1/ERK2 and MAPK3/ERK1) signaling and mediates mitogenic and stress-induced activation of transcription factors, regulates translation, and mediates cellular proliferation, survival, and differentiation. May function as tumor suppressor in epithelial ovarian cancer cells. {ECO:0000269|PubMed:16878154, ECO:0000269|PubMed:7623830}. |
| O95817 | BAG3 | S184 | Sugiyama | BAG family molecular chaperone regulator 3 (BAG-3) (Bcl-2-associated athanogene 3) (Bcl-2-binding protein Bis) (Docking protein CAIR-1) | Co-chaperone and adapter protein that connects different classes of molecular chaperones including heat shock proteins 70 (HSP70s), e.g. HSPA1A/HSP70 or HSPA8/HSC70, and small heat shock proteins (sHSPs), e.g. HSPB8 (PubMed:27884606, PubMed:30559338). Acts as a nucleotide-exchange factor (NEF) promoting the release of ADP from HSP70s, thereby triggering client protein release (PubMed:27884606, PubMed:30559338). Nucleotide release is mediated via BAG3 binding to the nucleotide-binding domain (NBD) of HSP70s, whereas client release is mediated via binding to the substrate-binding domain (SBD) (PubMed:27474739, PubMed:9873016). Has anti-apoptotic activity (PubMed:10597216). Plays a role in the HSF1 nucleocytoplasmic transport (PubMed:26159920). {ECO:0000269|PubMed:10597216, ECO:0000269|PubMed:24318877, ECO:0000269|PubMed:26159920, ECO:0000269|PubMed:27474739, ECO:0000269|PubMed:27884606, ECO:0000269|PubMed:30559338, ECO:0000269|PubMed:9873016}. |
Download
| reactome_id | name | p | -log10_p |
|---|---|---|---|
| R-HSA-9013957 | TLR3-mediated TICAM1-dependent programmed cell death | 0.031542 | 1.501 |
| R-HSA-8952158 | RUNX3 regulates BCL2L11 (BIM) transcription | 0.031542 | 1.501 |
| R-HSA-9673768 | Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | 0.036702 | 1.435 |
| R-HSA-9022537 | Loss of MECP2 binding ability to the NCoR/SMRT complex | 0.041835 | 1.378 |
| R-HSA-4411364 | Binding of TCF/LEF:CTNNB1 to target gene promoters | 0.052021 | 1.284 |
| R-HSA-2562578 | TRIF-mediated programmed cell death | 0.052021 | 1.284 |
| R-HSA-444257 | RSK activation | 0.057073 | 1.244 |
| R-HSA-167242 | Abortive elongation of HIV-1 transcript in the absence of Tat | 0.007472 | 2.127 |
| R-HSA-5218900 | CASP8 activity is inhibited | 0.062099 | 1.207 |
| R-HSA-5357786 | TNFR1-induced proapoptotic signaling | 0.008709 | 2.060 |
| R-HSA-933543 | NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | 0.072072 | 1.142 |
| R-HSA-167160 | RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | 0.010723 | 1.970 |
| R-HSA-77075 | RNA Pol II CTD phosphorylation and interaction with CE | 0.010723 | 1.970 |
| R-HSA-9931512 | Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | 0.077019 | 1.113 |
| R-HSA-5357956 | TNFR1-induced NF-kappa-B signaling pathway | 0.013696 | 1.863 |
| R-HSA-167243 | Tat-mediated HIV elongation arrest and recovery | 0.013696 | 1.863 |
| R-HSA-167238 | Pausing and recovery of Tat-mediated HIV elongation | 0.013696 | 1.863 |
| R-HSA-167158 | Formation of the HIV-1 Early Elongation Complex | 0.014489 | 1.839 |
| R-HSA-167287 | HIV elongation arrest and recovery | 0.014489 | 1.839 |
| R-HSA-113418 | Formation of the Early Elongation Complex | 0.014489 | 1.839 |
| R-HSA-167290 | Pausing and recovery of HIV elongation | 0.014489 | 1.839 |
| R-HSA-9661069 | Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | 0.086835 | 1.061 |
| R-HSA-5619107 | Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC... | 0.016132 | 1.792 |
| R-HSA-1855196 | IP3 and IP4 transport between cytosol and nucleus | 0.016983 | 1.770 |
| R-HSA-1855229 | IP6 and IP7 transport between cytosol and nucleus | 0.016983 | 1.770 |
| R-HSA-168927 | TICAM1, RIP1-mediated IKK complex recruitment | 0.096547 | 1.015 |
| R-HSA-1855170 | IPs transport between nucleus and cytosol | 0.018739 | 1.727 |
| R-HSA-159227 | Transport of the SLBP independent Mature mRNA | 0.018739 | 1.727 |
| R-HSA-159230 | Transport of the SLBP Dependant Mature mRNA | 0.019645 | 1.707 |
| R-HSA-1362300 | Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL... | 0.101365 | 0.994 |
| R-HSA-176412 | Phosphorylation of the APC/C | 0.101365 | 0.994 |
| R-HSA-5083636 | Defective GALNT12 causes CRCS1 | 0.101365 | 0.994 |
| R-HSA-5083625 | Defective GALNT3 causes HFTC | 0.101365 | 0.994 |
| R-HSA-9687136 | Aberrant regulation of mitotic exit in cancer due to RB1 defects | 0.101365 | 0.994 |
| R-HSA-9927426 | Developmental Lineage of Mammary Gland Alveolar Cells | 0.020569 | 1.687 |
| R-HSA-3301854 | Nuclear Pore Complex (NPC) Disassembly | 0.021511 | 1.667 |
| R-HSA-5083632 | Defective C1GALT1C1 causes TNPS | 0.110925 | 0.955 |
| R-HSA-159231 | Transport of Mature mRNA Derived from an Intronless Transcript | 0.025453 | 1.594 |
| R-HSA-159234 | Transport of Mature mRNAs Derived from Intronless Transcripts | 0.026482 | 1.577 |
| R-HSA-167152 | Formation of HIV elongation complex in the absence of HIV Tat | 0.026482 | 1.577 |
| R-HSA-937041 | IKK complex recruitment mediated by RIP1 | 0.120385 | 0.919 |
| R-HSA-174048 | APC/C:Cdc20 mediated degradation of Cyclin B | 0.120385 | 0.919 |
| R-HSA-9927418 | Developmental Lineage of Mammary Gland Luminal Epithelial Cells | 0.029665 | 1.528 |
| R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex | 0.125077 | 0.903 |
| R-HSA-72165 | mRNA Splicing - Minor Pathway | 0.034133 | 1.467 |
| R-HSA-383280 | Nuclear Receptor transcription pathway | 0.011214 | 1.950 |
| R-HSA-112382 | Formation of RNA Pol II elongation complex | 0.041289 | 1.384 |
| R-HSA-75955 | RNA Polymerase II Transcription Elongation | 0.042532 | 1.371 |
| R-HSA-167172 | Transcription of the HIV genome | 0.062756 | 1.202 |
| R-HSA-72172 | mRNA Splicing | 0.007150 | 2.146 |
| R-HSA-9614657 | FOXO-mediated transcription of cell death genes | 0.115667 | 0.937 |
| R-HSA-167169 | HIV Transcription Elongation | 0.026482 | 1.577 |
| R-HSA-72202 | Transport of Mature Transcript to Cytoplasm | 0.083961 | 1.076 |
| R-HSA-72086 | mRNA Capping | 0.015301 | 1.815 |
| R-HSA-72163 | mRNA Splicing - Major Pathway | 0.005816 | 2.235 |
| R-HSA-167246 | Tat-mediated elongation of the HIV-1 transcript | 0.026482 | 1.577 |
| R-HSA-72203 | Processing of Capped Intron-Containing Pre-mRNA | 0.001137 | 2.944 |
| R-HSA-167200 | Formation of HIV-1 elongation complex containing HIV-1 Tat | 0.025453 | 1.594 |
| R-HSA-156711 | Polo-like kinase mediated events | 0.115667 | 0.937 |
| R-HSA-5620916 | VxPx cargo-targeting to cilium | 0.125077 | 0.903 |
| R-HSA-164940 | Nef mediated downregulation of MHC class I complex cell surface expression | 0.057073 | 1.244 |
| R-HSA-8951936 | RUNX3 regulates p14-ARF | 0.081940 | 1.087 |
| R-HSA-9931521 | The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CL... | 0.106158 | 0.974 |
| R-HSA-159236 | Transport of Mature mRNA derived from an Intron-Containing Transcript | 0.070094 | 1.154 |
| R-HSA-6807505 | RNA polymerase II transcribes snRNA genes | 0.091996 | 1.036 |
| R-HSA-4641265 | Repression of WNT target genes | 0.081940 | 1.087 |
| R-HSA-674695 | RNA Polymerase II Pre-transcription Events | 0.071595 | 1.145 |
| R-HSA-9931509 | Expression of BMAL (ARNTL), CLOCK, and NPAS2 | 0.025453 | 1.594 |
| R-HSA-381340 | Transcriptional regulation of white adipocyte differentiation | 0.112128 | 0.950 |
| R-HSA-9832991 | Formation of the posterior neural plate | 0.002632 | 2.580 |
| R-HSA-9687139 | Aberrant regulation of mitotic cell cycle due to RB1 defects | 0.016132 | 1.792 |
| R-HSA-176407 | Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | 0.110925 | 0.955 |
| R-HSA-9924644 | Developmental Lineages of the Mammary Gland | 0.068605 | 1.164 |
| R-HSA-162599 | Late Phase of HIV Life Cycle | 0.010858 | 1.964 |
| R-HSA-5357905 | Regulation of TNFR1 signaling | 0.034133 | 1.467 |
| R-HSA-9692913 | SARS-CoV-1-mediated effects on programmed cell death | 0.031542 | 1.501 |
| R-HSA-8951430 | RUNX3 regulates WNT signaling | 0.052021 | 1.284 |
| R-HSA-9614399 | Regulation of localization of FOXO transcription factors | 0.072072 | 1.142 |
| R-HSA-9917777 | Epigenetic regulation by WDR5-containing histone modifying complexes | 0.064971 | 1.187 |
| R-HSA-75893 | TNF signaling | 0.046345 | 1.334 |
| R-HSA-140534 | Caspase activation via Death Receptors in the presence of ligand | 0.101365 | 0.994 |
| R-HSA-8875513 | MET interacts with TNS proteins | 0.026354 | 1.579 |
| R-HSA-3371378 | Regulation by c-FLIP | 0.057073 | 1.244 |
| R-HSA-9693928 | Defective RIPK1-mediated regulated necrosis | 0.067099 | 1.173 |
| R-HSA-202670 | ERKs are inactivated | 0.077019 | 1.113 |
| R-HSA-9659787 | Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | 0.086835 | 1.061 |
| R-HSA-1810476 | RIP-mediated NFkB activation via ZBP1 | 0.096547 | 1.015 |
| R-HSA-9603798 | Class I peroxisomal membrane protein import | 0.101365 | 0.994 |
| R-HSA-141430 | Inactivation of APC/C via direct inhibition of the APC/C complex | 0.106158 | 0.974 |
| R-HSA-180910 | Vpr-mediated nuclear import of PICs | 0.023448 | 1.630 |
| R-HSA-168325 | Viral Messenger RNA Synthesis | 0.006179 | 2.209 |
| R-HSA-73980 | RNA Polymerase III Transcription Termination | 0.115667 | 0.937 |
| R-HSA-8851708 | Signaling by FGFR2 IIIa TM | 0.120385 | 0.919 |
| R-HSA-168333 | NEP/NS2 Interacts with the Cellular Export Machinery | 0.032993 | 1.482 |
| R-HSA-8939236 | RUNX1 regulates transcription of genes involved in differentiation of HSCs | 0.013421 | 1.872 |
| R-HSA-9686347 | Microbial modulation of RIPK1-mediated regulated necrosis | 0.052021 | 1.284 |
| R-HSA-983168 | Antigen processing: Ubiquitination & Proteasome degradation | 0.023137 | 1.636 |
| R-HSA-418885 | DCC mediated attractive signaling | 0.004764 | 2.322 |
| R-HSA-162587 | HIV Life Cycle | 0.014638 | 1.835 |
| R-HSA-9909396 | Circadian clock | 0.045261 | 1.344 |
| R-HSA-111448 | Activation of NOXA and translocation to mitochondria | 0.031542 | 1.501 |
| R-HSA-139915 | Activation of PUMA and translocation to mitochondria | 0.052021 | 1.284 |
| R-HSA-9675126 | Diseases of mitotic cell cycle | 0.017852 | 1.748 |
| R-HSA-170822 | Regulation of Glucokinase by Glucokinase Regulatory Protein | 0.019645 | 1.707 |
| R-HSA-139853 | Elevation of cytosolic Ca2+ levels | 0.110925 | 0.955 |
| R-HSA-5578749 | Transcriptional regulation by small RNAs | 0.009235 | 2.035 |
| R-HSA-9707616 | Heme signaling | 0.054327 | 1.265 |
| R-HSA-2559582 | Senescence-Associated Secretory Phenotype (SASP) | 0.083961 | 1.076 |
| R-HSA-162906 | HIV Infection | 0.010605 | 1.974 |
| R-HSA-69416 | Dimerization of procaspase-8 | 0.057073 | 1.244 |
| R-HSA-9623433 | NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | 0.077019 | 1.113 |
| R-HSA-113501 | Inhibition of replication initiation of damaged DNA by RB1/E2F1 | 0.077019 | 1.113 |
| R-HSA-141405 | Inhibition of the proteolytic activity of APC/C required for the onset of anapha... | 0.106158 | 0.974 |
| R-HSA-9909649 | Regulation of PD-L1(CD274) transcription | 0.007478 | 2.126 |
| R-HSA-194441 | Metabolism of non-coding RNA | 0.050278 | 1.299 |
| R-HSA-191859 | snRNP Assembly | 0.050278 | 1.299 |
| R-HSA-446353 | Cell-extracellular matrix interactions | 0.096547 | 1.015 |
| R-HSA-9645723 | Diseases of programmed cell death | 0.095272 | 1.021 |
| R-HSA-69278 | Cell Cycle, Mitotic | 0.094306 | 1.025 |
| R-HSA-73887 | Death Receptor Signaling | 0.002365 | 2.626 |
| R-HSA-198753 | ERK/MAPK targets | 0.008709 | 2.060 |
| R-HSA-180746 | Nuclear import of Rev protein | 0.020569 | 1.687 |
| R-HSA-5689896 | Ovarian tumor domain proteases | 0.023448 | 1.630 |
| R-HSA-199920 | CREB phosphorylation | 0.046942 | 1.328 |
| R-HSA-8849469 | PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | 0.057073 | 1.244 |
| R-HSA-198693 | AKT phosphorylates targets in the nucleus | 0.062099 | 1.207 |
| R-HSA-9839394 | TGFBR3 expression | 0.012169 | 1.915 |
| R-HSA-177243 | Interactions of Rev with host cellular proteins | 0.026482 | 1.577 |
| R-HSA-176033 | Interactions of Vpr with host cellular proteins | 0.026482 | 1.577 |
| R-HSA-168271 | Transport of Ribonucleoproteins into the Host Nucleus | 0.027526 | 1.560 |
| R-HSA-113510 | E2F mediated regulation of DNA replication | 0.120385 | 0.919 |
| R-HSA-9609690 | HCMV Early Events | 0.108280 | 0.965 |
| R-HSA-8878159 | Transcriptional regulation by RUNX3 | 0.020437 | 1.690 |
| R-HSA-1640170 | Cell Cycle | 0.095018 | 1.022 |
| R-HSA-9617629 | Regulation of FOXO transcriptional activity by acetylation | 0.081940 | 1.087 |
| R-HSA-881907 | Gastrin-CREB signalling pathway via PKC and MAPK | 0.120385 | 0.919 |
| R-HSA-9762293 | Regulation of CDH11 gene transcription | 0.062099 | 1.207 |
| R-HSA-525793 | Myogenesis | 0.012923 | 1.889 |
| R-HSA-168273 | Influenza Viral RNA Transcription and Replication | 0.065865 | 1.181 |
| R-HSA-9823739 | Formation of the anterior neural plate | 0.004764 | 2.322 |
| R-HSA-8851805 | MET activates RAS signaling | 0.081940 | 1.087 |
| R-HSA-9005895 | Pervasive developmental disorders | 0.081940 | 1.087 |
| R-HSA-9697154 | Disorders of Nervous System Development | 0.081940 | 1.087 |
| R-HSA-9005891 | Loss of function of MECP2 in Rett syndrome | 0.081940 | 1.087 |
| R-HSA-164938 | Nef-mediates down modulation of cell surface receptors by recruiting them to cla... | 0.110925 | 0.955 |
| R-HSA-165054 | Rev-mediated nuclear export of HIV RNA | 0.024442 | 1.612 |
| R-HSA-168274 | Export of Viral Ribonucleoproteins from Nucleus | 0.034133 | 1.467 |
| R-HSA-74160 | Gene expression (Transcription) | 0.033060 | 1.481 |
| R-HSA-450282 | MAPK targets/ Nuclear events mediated by MAP kinases | 0.015301 | 1.815 |
| R-HSA-8953854 | Metabolism of RNA | 0.086898 | 1.061 |
| R-HSA-6804114 | TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | 0.106158 | 0.974 |
| R-HSA-1606322 | ZBP1(DAI) mediated induction of type I IFNs | 0.115667 | 0.937 |
| R-HSA-73857 | RNA Polymerase II Transcription | 0.070584 | 1.151 |
| R-HSA-438064 | Post NMDA receptor activation events | 0.093630 | 1.029 |
| R-HSA-2559583 | Cellular Senescence | 0.091061 | 1.041 |
| R-HSA-6796648 | TP53 Regulates Transcription of DNA Repair Genes | 0.077699 | 1.110 |
| R-HSA-9675151 | Disorders of Developmental Biology | 0.106158 | 0.974 |
| R-HSA-168276 | NS1 Mediated Effects on Host Pathways | 0.025453 | 1.594 |
| R-HSA-5357801 | Programmed Cell Death | 0.032812 | 1.484 |
| R-HSA-2980766 | Nuclear Envelope Breakdown | 0.047643 | 1.322 |
| R-HSA-5687128 | MAPK6/MAPK4 signaling | 0.088755 | 1.052 |
| R-HSA-9616222 | Transcriptional regulation of granulopoiesis | 0.054327 | 1.265 |
| R-HSA-162909 | Host Interactions of HIV factors | 0.038090 | 1.419 |
| R-HSA-373752 | Netrin-1 signaling | 0.031868 | 1.497 |
| R-HSA-193648 | NRAGE signals death through JNK | 0.005025 | 2.299 |
| R-HSA-9764725 | Negative Regulation of CDH1 Gene Transcription | 0.005936 | 2.226 |
| R-HSA-6784531 | tRNA processing in the nucleus | 0.054327 | 1.265 |
| R-HSA-3371453 | Regulation of HSF1-mediated heat shock response | 0.022972 | 1.639 |
| R-HSA-212436 | Generic Transcription Pathway | 0.039015 | 1.409 |
| R-HSA-9834899 | Specification of the neural plate border | 0.120385 | 0.919 |
| R-HSA-9764560 | Regulation of CDH1 Gene Transcription | 0.008625 | 2.064 |
| R-HSA-937061 | TRIF (TICAM1)-mediated TLR4 signaling | 0.027946 | 1.554 |
| R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | 0.046345 | 1.334 |
| R-HSA-166166 | MyD88-independent TLR4 cascade | 0.027946 | 1.554 |
| R-HSA-168164 | Toll Like Receptor 3 (TLR3) Cascade | 0.025117 | 1.600 |
| R-HSA-9909648 | Regulation of PD-L1(CD274) expression | 0.082925 | 1.081 |
| R-HSA-198725 | Nuclear Events (kinase and transcription factor activation) | 0.009235 | 2.035 |
| R-HSA-168255 | Influenza Infection | 0.090026 | 1.046 |
| R-HSA-264870 | Caspase-mediated cleavage of cytoskeletal proteins | 0.062099 | 1.207 |
| R-HSA-9842663 | Signaling by LTK | 0.081940 | 1.087 |
| R-HSA-211000 | Gene Silencing by RNA | 0.026229 | 1.581 |
| R-HSA-442755 | Activation of NMDA receptors and postsynaptic events | 0.122588 | 0.912 |
| R-HSA-389948 | Co-inhibition by PD-1 | 0.112771 | 0.948 |
| R-HSA-450294 | MAP kinase activation | 0.052965 | 1.276 |
| R-HSA-1266738 | Developmental Biology | 0.001346 | 2.871 |
| R-HSA-9839373 | Signaling by TGFBR3 | 0.034133 | 1.467 |
| R-HSA-70171 | Glycolysis | 0.119075 | 0.924 |
| R-HSA-69273 | Cyclin A/B1/B2 associated events during G2/M transition | 0.018739 | 1.727 |
| R-HSA-448424 | Interleukin-17 signaling | 0.065658 | 1.183 |
| R-HSA-1181150 | Signaling by NODAL | 0.125077 | 0.903 |
| R-HSA-446728 | Cell junction organization | 0.075840 | 1.120 |
| R-HSA-9759476 | Regulation of Homotypic Cell-Cell Adhesion | 0.108280 | 0.965 |
| R-HSA-166016 | Toll Like Receptor 4 (TLR4) Cascade | 0.059722 | 1.224 |
| R-HSA-109581 | Apoptosis | 0.016061 | 1.794 |
| R-HSA-983169 | Class I MHC mediated antigen processing & presentation | 0.065543 | 1.183 |
| R-HSA-9764274 | Regulation of Expression and Function of Type I Classical Cadherins | 0.083924 | 1.076 |
| R-HSA-9764265 | Regulation of CDH1 Expression and Function | 0.083924 | 1.076 |
| R-HSA-9764790 | Positive Regulation of CDH1 Gene Transcription | 0.067099 | 1.173 |
| R-HSA-1500931 | Cell-Cell communication | 0.105769 | 0.976 |
| R-HSA-168898 | Toll-like Receptor Cascades | 0.102769 | 0.988 |
| R-HSA-3371556 | Cellular response to heat stress | 0.036063 | 1.443 |
| R-HSA-416482 | G alpha (12/13) signalling events | 0.011214 | 1.950 |
| R-HSA-2262752 | Cellular responses to stress | 0.102698 | 0.988 |
| R-HSA-1169408 | ISG15 antiviral mechanism | 0.073105 | 1.136 |
| R-HSA-170834 | Signaling by TGF-beta Receptor Complex | 0.113854 | 0.944 |
| R-HSA-204998 | Cell death signalling via NRAGE, NRIF and NADE | 0.009549 | 2.020 |
| R-HSA-6806834 | Signaling by MET | 0.080811 | 1.093 |
| R-HSA-9758941 | Gastrulation | 0.060582 | 1.218 |
| R-HSA-9006936 | Signaling by TGFB family members | 0.015482 | 1.810 |
| R-HSA-111465 | Apoptotic cleavage of cellular proteins | 0.017852 | 1.748 |
| R-HSA-162582 | Signal Transduction | 0.079127 | 1.102 |
| R-HSA-187037 | Signaling by NTRK1 (TRKA) | 0.041597 | 1.381 |
| R-HSA-1280218 | Adaptive Immune System | 0.115874 | 0.936 |
| R-HSA-422475 | Axon guidance | 0.082598 | 1.083 |
| R-HSA-975871 | MyD88 cascade initiated on plasma membrane | 0.115588 | 0.937 |
| R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling | 0.026819 | 1.572 |
| R-HSA-168142 | Toll Like Receptor 10 (TLR10) Cascade | 0.115588 | 0.937 |
| R-HSA-168176 | Toll Like Receptor 5 (TLR5) Cascade | 0.115588 | 0.937 |
| R-HSA-9675108 | Nervous system development | 0.103802 | 0.984 |
| R-HSA-75153 | Apoptotic execution phase | 0.034133 | 1.467 |
| R-HSA-166520 | Signaling by NTRKs | 0.059722 | 1.224 |
| R-HSA-1169410 | Antiviral mechanism by IFN-stimulated genes | 0.064971 | 1.187 |
| R-HSA-168256 | Immune System | 0.098882 | 1.005 |
| R-HSA-9006934 | Signaling by Receptor Tyrosine Kinases | 0.020156 | 1.696 |
| R-HSA-193704 | p75 NTR receptor-mediated signalling | 0.021431 | 1.669 |
| R-HSA-5663202 | Diseases of signal transduction by growth factor receptors and second messengers | 0.067387 | 1.171 |
| R-HSA-5619507 | Activation of HOX genes during differentiation | 0.127905 | 0.893 |
| R-HSA-5617472 | Activation of anterior HOX genes in hindbrain development during early embryogen... | 0.127905 | 0.893 |
| R-HSA-179409 | APC-Cdc20 mediated degradation of Nek2A | 0.129744 | 0.887 |
| R-HSA-1280215 | Cytokine Signaling in Immune system | 0.129955 | 0.886 |
| R-HSA-449147 | Signaling by Interleukins | 0.131707 | 0.880 |
| R-HSA-9725370 | Signaling by ALK fusions and activated point mutants | 0.133277 | 0.875 |
| R-HSA-9700206 | Signaling by ALK in cancer | 0.133277 | 0.875 |
| R-HSA-9617828 | FOXO-mediated transcription of cell cycle genes | 0.134387 | 0.872 |
| R-HSA-9825892 | Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | 0.134387 | 0.872 |
| R-HSA-9671555 | Signaling by PDGFR in disease | 0.134387 | 0.872 |
| R-HSA-418990 | Adherens junctions interactions | 0.135037 | 0.870 |
| R-HSA-9734779 | Developmental Cell Lineages of the Integumentary System | 0.135079 | 0.869 |
| R-HSA-975138 | TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | 0.135079 | 0.869 |
| R-HSA-975155 | MyD88 dependent cascade initiated on endosome | 0.136886 | 0.864 |
| R-HSA-6803529 | FGFR2 alternative splicing | 0.139006 | 0.857 |
| R-HSA-350054 | Notch-HLH transcription pathway | 0.139006 | 0.857 |
| R-HSA-1483249 | Inositol phosphate metabolism | 0.142341 | 0.847 |
| R-HSA-977068 | Termination of O-glycan biosynthesis | 0.143600 | 0.843 |
| R-HSA-9634638 | Estrogen-dependent nuclear events downstream of ESR-membrane signaling | 0.143600 | 0.843 |
| R-HSA-164952 | The role of Nef in HIV-1 replication and disease pathogenesis | 0.143600 | 0.843 |
| R-HSA-5674400 | Constitutive Signaling by AKT1 E17K in Cancer | 0.143600 | 0.843 |
| R-HSA-168181 | Toll Like Receptor 7/8 (TLR7/8) Cascade | 0.144170 | 0.841 |
| R-HSA-8878171 | Transcriptional regulation by RUNX1 | 0.144839 | 0.839 |
| R-HSA-8863678 | Neurodegenerative Diseases | 0.148170 | 0.829 |
| R-HSA-8862803 | Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's dis... | 0.148170 | 0.829 |
| R-HSA-168138 | Toll Like Receptor 9 (TLR9) Cascade | 0.149685 | 0.825 |
| R-HSA-203927 | MicroRNA (miRNA) biogenesis | 0.152716 | 0.816 |
| R-HSA-5601884 | PIWI-interacting RNA (piRNA) biogenesis | 0.152716 | 0.816 |
| R-HSA-373760 | L1CAM interactions | 0.153386 | 0.814 |
| R-HSA-70326 | Glucose metabolism | 0.155243 | 0.809 |
| R-HSA-9931510 | Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock gene... | 0.157237 | 0.803 |
| R-HSA-3295583 | TRP channels | 0.157237 | 0.803 |
| R-HSA-5357769 | Caspase activation via extrinsic apoptotic signalling pathway | 0.157237 | 0.803 |
| R-HSA-9615933 | Postmitotic nuclear pore complex (NPC) reformation | 0.157237 | 0.803 |
| R-HSA-166058 | MyD88:MAL(TIRAP) cascade initiated on plasma membrane | 0.158971 | 0.799 |
| R-HSA-168188 | Toll Like Receptor TLR6:TLR2 Cascade | 0.158971 | 0.799 |
| R-HSA-9824446 | Viral Infection Pathways | 0.159007 | 0.799 |
| R-HSA-68875 | Mitotic Prophase | 0.160841 | 0.794 |
| R-HSA-445095 | Interaction between L1 and Ankyrins | 0.161735 | 0.791 |
| R-HSA-9734009 | Defective Intrinsic Pathway for Apoptosis | 0.161735 | 0.791 |
| R-HSA-9841251 | Mitochondrial unfolded protein response (UPRmt) | 0.161735 | 0.791 |
| R-HSA-168179 | Toll Like Receptor TLR1:TLR2 Cascade | 0.164594 | 0.784 |
| R-HSA-181438 | Toll Like Receptor 2 (TLR2) Cascade | 0.164594 | 0.784 |
| R-HSA-9619483 | Activation of AMPK downstream of NMDARs | 0.166209 | 0.779 |
| R-HSA-8953897 | Cellular responses to stimuli | 0.169556 | 0.771 |
| R-HSA-418360 | Platelet calcium homeostasis | 0.170660 | 0.768 |
| R-HSA-9759475 | Regulation of CDH11 Expression and Function | 0.170660 | 0.768 |
| R-HSA-9851695 | Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | 0.172145 | 0.764 |
| R-HSA-9841922 | MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesi... | 0.172145 | 0.764 |
| R-HSA-9818564 | Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | 0.172145 | 0.764 |
| R-HSA-9933387 | RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | 0.175087 | 0.757 |
| R-HSA-114452 | Activation of BH3-only proteins | 0.175087 | 0.757 |
| R-HSA-9609646 | HCMV Infection | 0.175561 | 0.756 |
| R-HSA-421270 | Cell-cell junction organization | 0.176879 | 0.752 |
| R-HSA-5694530 | Cargo concentration in the ER | 0.179491 | 0.746 |
| R-HSA-597592 | Post-translational protein modification | 0.183237 | 0.737 |
| R-HSA-388841 | Regulation of T cell activation by CD28 family | 0.183514 | 0.736 |
| R-HSA-1538133 | G0 and Early G1 | 0.183871 | 0.735 |
| R-HSA-2173795 | Downregulation of SMAD2/3:SMAD4 transcriptional activity | 0.183871 | 0.735 |
| R-HSA-9843745 | Adipogenesis | 0.185495 | 0.732 |
| R-HSA-442742 | CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | 0.188229 | 0.725 |
| R-HSA-5675482 | Regulation of necroptotic cell death | 0.188229 | 0.725 |
| R-HSA-5693568 | Resolution of D-loop Structures through Holliday Junction Intermediates | 0.188229 | 0.725 |
| R-HSA-9764260 | Regulation of Expression and Function of Type II Classical Cadherins | 0.188229 | 0.725 |
| R-HSA-9022692 | Regulation of MECP2 expression and activity | 0.188229 | 0.725 |
| R-HSA-5693537 | Resolution of D-Loop Structures | 0.192563 | 0.715 |
| R-HSA-416476 | G alpha (q) signalling events | 0.194267 | 0.712 |
| R-HSA-9772755 | Formation of WDR5-containing histone-modifying complexes | 0.201164 | 0.696 |
| R-HSA-2559585 | Oncogene Induced Senescence | 0.201164 | 0.696 |
| R-HSA-69205 | G1/S-Specific Transcription | 0.205430 | 0.687 |
| R-HSA-749476 | RNA Polymerase III Abortive And Retractive Initiation | 0.205430 | 0.687 |
| R-HSA-1839126 | FGFR2 mutant receptor activation | 0.205430 | 0.687 |
| R-HSA-8853659 | RET signaling | 0.205430 | 0.687 |
| R-HSA-74158 | RNA Polymerase III Transcription | 0.205430 | 0.687 |
| R-HSA-3769402 | Deactivation of the beta-catenin transactivating complex | 0.209673 | 0.678 |
| R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | 0.209673 | 0.678 |
| R-HSA-9705671 | SARS-CoV-2 activates/modulates innate and adaptive immune responses | 0.210649 | 0.676 |
| R-HSA-5213460 | RIPK1-mediated regulated necrosis | 0.213895 | 0.670 |
| R-HSA-8875878 | MET promotes cell motility | 0.213895 | 0.670 |
| R-HSA-8953750 | Transcriptional Regulation by E2F6 | 0.218093 | 0.661 |
| R-HSA-199977 | ER to Golgi Anterograde Transport | 0.220419 | 0.657 |
| R-HSA-73779 | RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | 0.222270 | 0.653 |
| R-HSA-9670095 | Inhibition of DNA recombination at telomere | 0.222270 | 0.653 |
| R-HSA-1251985 | Nuclear signaling by ERBB4 | 0.222270 | 0.653 |
| R-HSA-69242 | S Phase | 0.222378 | 0.653 |
| R-HSA-9679191 | Potential therapeutics for SARS | 0.226301 | 0.645 |
| R-HSA-9820841 | M-decay: degradation of maternal mRNAs by maternally stored factors | 0.226425 | 0.645 |
| R-HSA-3214841 | PKMTs methylate histone lysines | 0.226425 | 0.645 |
| R-HSA-9607240 | FLT3 Signaling | 0.226425 | 0.645 |
| R-HSA-8853884 | Transcriptional Regulation by VENTX | 0.226425 | 0.645 |
| R-HSA-167162 | RNA Polymerase II HIV Promoter Escape | 0.230558 | 0.637 |
| R-HSA-167161 | HIV Transcription Initiation | 0.230558 | 0.637 |
| R-HSA-75953 | RNA Polymerase II Transcription Initiation | 0.230558 | 0.637 |
| R-HSA-9615017 | FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | 0.230558 | 0.637 |
| R-HSA-1989781 | PPARA activates gene expression | 0.236129 | 0.627 |
| R-HSA-73776 | RNA Polymerase II Promoter Escape | 0.238758 | 0.622 |
| R-HSA-400206 | Regulation of lipid metabolism by PPARalpha | 0.240067 | 0.620 |
| R-HSA-9610379 | HCMV Late Events | 0.240067 | 0.620 |
| R-HSA-69231 | Cyclin D associated events in G1 | 0.242826 | 0.615 |
| R-HSA-69236 | G1 Phase | 0.242826 | 0.615 |
| R-HSA-3928662 | EPHB-mediated forward signaling | 0.242826 | 0.615 |
| R-HSA-76042 | RNA Polymerase II Transcription Initiation And Promoter Clearance | 0.246872 | 0.608 |
| R-HSA-6783310 | Fanconi Anemia Pathway | 0.246872 | 0.608 |
| R-HSA-6781823 | Formation of TC-NER Pre-Incision Complex | 0.250896 | 0.601 |
| R-HSA-174084 | Autodegradation of Cdh1 by Cdh1:APC/C | 0.250896 | 0.601 |
| R-HSA-174154 | APC/C:Cdc20 mediated degradation of Securin | 0.254900 | 0.594 |
| R-HSA-6811440 | Retrograde transport at the Trans-Golgi-Network | 0.254900 | 0.594 |
| R-HSA-437239 | Recycling pathway of L1 | 0.254900 | 0.594 |
| R-HSA-9725371 | Nuclear events stimulated by ALK signaling in cancer | 0.258882 | 0.587 |
| R-HSA-9031628 | NGF-stimulated transcription | 0.258882 | 0.587 |
| R-HSA-5619102 | SLC transporter disorders | 0.259802 | 0.585 |
| R-HSA-2122947 | NOTCH1 Intracellular Domain Regulates Transcription | 0.262844 | 0.580 |
| R-HSA-9748787 | Azathioprine ADME | 0.266784 | 0.574 |
| R-HSA-5655253 | Signaling by FGFR2 in disease | 0.266784 | 0.574 |
| R-HSA-72306 | tRNA processing | 0.267707 | 0.572 |
| R-HSA-174184 | Cdc20:Phospho-APC/C mediated degradation of Cyclin A | 0.274603 | 0.561 |
| R-HSA-8866654 | E3 ubiquitin ligases ubiquitinate target proteins | 0.274603 | 0.561 |
| R-HSA-212165 | Epigenetic regulation of gene expression | 0.277417 | 0.557 |
| R-HSA-179419 | APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of th... | 0.278481 | 0.555 |
| R-HSA-174178 | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins ... | 0.278481 | 0.555 |
| R-HSA-69017 | CDK-mediated phosphorylation and removal of Cdc6 | 0.282339 | 0.549 |
| R-HSA-176409 | APC/C:Cdc20 mediated degradation of mitotic proteins | 0.286176 | 0.543 |
| R-HSA-3214815 | HDACs deacetylate histones | 0.286176 | 0.543 |
| R-HSA-9753281 | Paracetamol ADME | 0.286176 | 0.543 |
| R-HSA-176814 | Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | 0.289993 | 0.538 |
| R-HSA-6782210 | Gap-filling DNA repair synthesis and ligation in TC-NER | 0.289993 | 0.538 |
| R-HSA-5578775 | Ion homeostasis | 0.289993 | 0.538 |
| R-HSA-109606 | Intrinsic Pathway for Apoptosis | 0.289993 | 0.538 |
| R-HSA-5621480 | Dectin-2 family | 0.293790 | 0.532 |
| R-HSA-6791312 | TP53 Regulates Transcription of Cell Cycle Genes | 0.293790 | 0.532 |
| R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex | 0.297567 | 0.526 |
| R-HSA-6782135 | Dual incision in TC-NER | 0.297567 | 0.526 |
| R-HSA-9029569 | NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflu... | 0.297567 | 0.526 |
| R-HSA-69275 | G2/M Transition | 0.299295 | 0.524 |
| R-HSA-9033241 | Peroxisomal protein import | 0.301324 | 0.521 |
| R-HSA-453274 | Mitotic G2-G2/M phases | 0.303233 | 0.518 |
| R-HSA-2894862 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | 0.305061 | 0.516 |
| R-HSA-2644602 | Signaling by NOTCH1 PEST Domain Mutants in Cancer | 0.305061 | 0.516 |
| R-HSA-2894858 | Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | 0.305061 | 0.516 |
| R-HSA-2644606 | Constitutive Signaling by NOTCH1 PEST Domain Mutants | 0.305061 | 0.516 |
| R-HSA-2644603 | Signaling by NOTCH1 in Cancer | 0.305061 | 0.516 |
| R-HSA-176408 | Regulation of APC/C activators between G1/S and early anaphase | 0.312476 | 0.505 |
| R-HSA-1660499 | Synthesis of PIPs at the plasma membrane | 0.312476 | 0.505 |
| R-HSA-8848021 | Signaling by PTK6 | 0.316154 | 0.500 |
| R-HSA-9006927 | Signaling by Non-Receptor Tyrosine Kinases | 0.316154 | 0.500 |
| R-HSA-5685942 | HDR through Homologous Recombination (HRR) | 0.330673 | 0.481 |
| R-HSA-948021 | Transport to the Golgi and subsequent modification | 0.330681 | 0.481 |
| R-HSA-913709 | O-linked glycosylation of mucins | 0.334255 | 0.476 |
| R-HSA-5218859 | Regulated Necrosis | 0.334255 | 0.476 |
| R-HSA-8936459 | RUNX1 regulates genes involved in megakaryocyte differentiation and platelet fun... | 0.334255 | 0.476 |
| R-HSA-9662360 | Sensory processing of sound by inner hair cells of the cochlea | 0.334255 | 0.476 |
| R-HSA-9006931 | Signaling by Nuclear Receptors | 0.335762 | 0.474 |
| R-HSA-195253 | Degradation of beta-catenin by the destruction complex | 0.341362 | 0.467 |
| R-HSA-69202 | Cyclin E associated events during G1/S transition | 0.341362 | 0.467 |
| R-HSA-1834949 | Cytosolic sensors of pathogen-associated DNA | 0.341362 | 0.467 |
| R-HSA-453276 | Regulation of mitotic cell cycle | 0.344887 | 0.462 |
| R-HSA-174143 | APC/C-mediated degradation of cell cycle proteins | 0.344887 | 0.462 |
| R-HSA-3906995 | Diseases associated with O-glycosylation of proteins | 0.344887 | 0.462 |
| R-HSA-5620920 | Cargo trafficking to the periciliary membrane | 0.344887 | 0.462 |
| R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry | 0.348393 | 0.458 |
| R-HSA-69052 | Switching of origins to a post-replicative state | 0.351882 | 0.454 |
| R-HSA-4086398 | Ca2+ pathway | 0.351882 | 0.454 |
| R-HSA-112314 | Neurotransmitter receptors and postsynaptic signal transmission | 0.352048 | 0.453 |
| R-HSA-1236394 | Signaling by ERBB4 | 0.355351 | 0.449 |
| R-HSA-1226099 | Signaling by FGFR in disease | 0.355351 | 0.449 |
| R-HSA-6781827 | Transcription-Coupled Nucleotide Excision Repair (TC-NER) | 0.358803 | 0.445 |
| R-HSA-8852135 | Protein ubiquitination | 0.358803 | 0.445 |
| R-HSA-68882 | Mitotic Anaphase | 0.359764 | 0.444 |
| R-HSA-2555396 | Mitotic Metaphase and Anaphase | 0.361688 | 0.442 |
| R-HSA-1980143 | Signaling by NOTCH1 | 0.362236 | 0.441 |
| R-HSA-68886 | M Phase | 0.364971 | 0.438 |
| R-HSA-9024446 | NR1H2 and NR1H3-mediated signaling | 0.365650 | 0.437 |
| R-HSA-913531 | Interferon Signaling | 0.366428 | 0.436 |
| R-HSA-8951664 | Neddylation | 0.369362 | 0.433 |
| R-HSA-9679506 | SARS-CoV Infections | 0.370123 | 0.432 |
| R-HSA-9659379 | Sensory processing of sound | 0.372426 | 0.429 |
| R-HSA-5654738 | Signaling by FGFR2 | 0.375787 | 0.425 |
| R-HSA-2995410 | Nuclear Envelope (NE) Reassembly | 0.375787 | 0.425 |
| R-HSA-9833482 | PKR-mediated signaling | 0.375787 | 0.425 |
| R-HSA-2151201 | Transcriptional activation of mitochondrial biogenesis | 0.379130 | 0.421 |
| R-HSA-9705683 | SARS-CoV-2-host interactions | 0.382707 | 0.417 |
| R-HSA-9707564 | Cytoprotection by HMOX1 | 0.385763 | 0.414 |
| R-HSA-2565942 | Regulation of PLK1 Activity at G2/M Transition | 0.389054 | 0.410 |
| R-HSA-3247509 | Chromatin modifying enzymes | 0.394052 | 0.404 |
| R-HSA-8939211 | ESR-mediated signaling | 0.399691 | 0.398 |
| R-HSA-157118 | Signaling by NOTCH | 0.405305 | 0.392 |
| R-HSA-1912408 | Pre-NOTCH Transcription and Translation | 0.414756 | 0.382 |
| R-HSA-8986944 | Transcriptional Regulation by MECP2 | 0.414756 | 0.382 |
| R-HSA-5619115 | Disorders of transmembrane transporters | 0.418309 | 0.379 |
| R-HSA-2682334 | EPH-Ephrin signaling | 0.421013 | 0.376 |
| R-HSA-4839726 | Chromatin organization | 0.421999 | 0.375 |
| R-HSA-983695 | Antigen activates B Cell Receptor (BCR) leading to generation of second messenge... | 0.424117 | 0.373 |
| R-HSA-68867 | Assembly of the pre-replicative complex | 0.424117 | 0.373 |
| R-HSA-168928 | DDX58/IFIH1-mediated induction of interferon-alpha/beta | 0.430275 | 0.366 |
| R-HSA-5688426 | Deubiquitination | 0.432998 | 0.364 |
| R-HSA-6807878 | COPI-mediated anterograde transport | 0.436368 | 0.360 |
| R-HSA-157579 | Telomere Maintenance | 0.439390 | 0.357 |
| R-HSA-8957275 | Post-translational protein phosphorylation | 0.442396 | 0.354 |
| R-HSA-190236 | Signaling by FGFR | 0.442396 | 0.354 |
| R-HSA-9614085 | FOXO-mediated transcription | 0.445387 | 0.351 |
| R-HSA-9734767 | Developmental Cell Lineages | 0.447492 | 0.349 |
| R-HSA-69618 | Mitotic Spindle Checkpoint | 0.448361 | 0.348 |
| R-HSA-382556 | ABC-family proteins mediated transport | 0.448361 | 0.348 |
| R-HSA-9009391 | Extra-nuclear estrogen signaling | 0.451320 | 0.346 |
| R-HSA-2559580 | Oxidative Stress Induced Senescence | 0.454263 | 0.343 |
| R-HSA-1483255 | PI Metabolism | 0.454263 | 0.343 |
| R-HSA-1643685 | Disease | 0.458913 | 0.338 |
| R-HSA-163125 | Post-translational modification: synthesis of GPI-anchored proteins | 0.462998 | 0.334 |
| R-HSA-9833110 | RSV-host interactions | 0.462998 | 0.334 |
| R-HSA-5696398 | Nucleotide Excision Repair | 0.465879 | 0.332 |
| R-HSA-418346 | Platelet homeostasis | 0.468745 | 0.329 |
| R-HSA-9692914 | SARS-CoV-1-host interactions | 0.468745 | 0.329 |
| R-HSA-69239 | Synthesis of DNA | 0.471596 | 0.326 |
| R-HSA-2672351 | Stimuli-sensing channels | 0.474431 | 0.324 |
| R-HSA-69002 | DNA Replication Pre-Initiation | 0.477252 | 0.321 |
| R-HSA-3700989 | Transcriptional Regulation by TP53 | 0.482742 | 0.316 |
| R-HSA-1912422 | Pre-NOTCH Expression and Processing | 0.488385 | 0.311 |
| R-HSA-5693567 | HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | 0.491131 | 0.309 |
| R-HSA-381426 | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-l... | 0.493863 | 0.306 |
| R-HSA-1592230 | Mitochondrial biogenesis | 0.504646 | 0.297 |
| R-HSA-2219528 | PI3K/AKT Signaling in Cancer | 0.507306 | 0.295 |
| R-HSA-5693538 | Homology Directed Repair | 0.507306 | 0.295 |
| R-HSA-73886 | Chromosome Maintenance | 0.515202 | 0.288 |
| R-HSA-9816359 | Maternal to zygotic transition (MZT) | 0.520396 | 0.284 |
| R-HSA-6809371 | Formation of the cornified envelope | 0.522973 | 0.282 |
| R-HSA-69206 | G1/S Transition | 0.528085 | 0.277 |
| R-HSA-114608 | Platelet degranulation | 0.533143 | 0.273 |
| R-HSA-1852241 | Organelle biogenesis and maintenance | 0.544423 | 0.264 |
| R-HSA-5576891 | Cardiac conduction | 0.545554 | 0.263 |
| R-HSA-112315 | Transmission across Chemical Synapses | 0.549194 | 0.260 |
| R-HSA-76005 | Response to elevated platelet cytosolic Ca2+ | 0.550427 | 0.259 |
| R-HSA-9018519 | Estrogen-dependent gene expression | 0.560018 | 0.252 |
| R-HSA-3858494 | Beta-catenin independent WNT signaling | 0.560018 | 0.252 |
| R-HSA-5173105 | O-linked glycosylation | 0.562384 | 0.250 |
| R-HSA-9820952 | Respiratory Syncytial Virus Infection Pathway | 0.562384 | 0.250 |
| R-HSA-5663205 | Infectious disease | 0.571449 | 0.243 |
| R-HSA-453279 | Mitotic G1 phase and G1/S transition | 0.585363 | 0.233 |
| R-HSA-5683057 | MAPK family signaling cascades | 0.586117 | 0.232 |
| R-HSA-9694516 | SARS-CoV-2 Infection | 0.589092 | 0.230 |
| R-HSA-9856651 | MITF-M-dependent gene expression | 0.594217 | 0.226 |
| R-HSA-9609507 | Protein localization | 0.600735 | 0.221 |
| R-HSA-69306 | DNA Replication | 0.600735 | 0.221 |
| R-HSA-5693532 | DNA Double-Strand Break Repair | 0.600735 | 0.221 |
| R-HSA-73894 | DNA Repair | 0.605181 | 0.218 |
| R-HSA-983705 | Signaling by the B Cell Receptor (BCR) | 0.611368 | 0.214 |
| R-HSA-388396 | GPCR downstream signalling | 0.618794 | 0.208 |
| R-HSA-2467813 | Separation of Sister Chromatids | 0.623760 | 0.205 |
| R-HSA-5621481 | C-type lectin receptors (CLRs) | 0.639676 | 0.194 |
| R-HSA-5689880 | Ub-specific processing proteases | 0.643550 | 0.191 |
| R-HSA-9678108 | SARS-CoV-1 Infection | 0.647383 | 0.189 |
| R-HSA-392499 | Metabolism of proteins | 0.661285 | 0.180 |
| R-HSA-201681 | TCF dependent signaling in response to WNT | 0.662311 | 0.179 |
| R-HSA-3781865 | Diseases of glycosylation | 0.664132 | 0.178 |
| R-HSA-983712 | Ion channel transport | 0.673095 | 0.172 |
| R-HSA-5617833 | Cilium Assembly | 0.674859 | 0.171 |
| R-HSA-446203 | Asparagine N-linked glycosylation | 0.688285 | 0.162 |
| R-HSA-6811442 | Intra-Golgi and retrograde Golgi-to-ER traffic | 0.691990 | 0.160 |
| R-HSA-372790 | Signaling by GPCR | 0.696075 | 0.157 |
| R-HSA-199991 | Membrane Trafficking | 0.698396 | 0.156 |
| R-HSA-6805567 | Keratinization | 0.703447 | 0.153 |
| R-HSA-397014 | Muscle contraction | 0.712932 | 0.147 |
| R-HSA-9730414 | MITF-M-regulated melanocyte development | 0.714483 | 0.146 |
| R-HSA-9748784 | Drug ADME | 0.722117 | 0.141 |
| R-HSA-71387 | Metabolism of carbohydrates and carbohydrate derivatives | 0.725858 | 0.139 |
| R-HSA-112316 | Neuronal System | 0.739591 | 0.131 |
| R-HSA-69620 | Cell Cycle Checkpoints | 0.776347 | 0.110 |
| R-HSA-9711123 | Cellular response to chemical stress | 0.788180 | 0.103 |
| R-HSA-76002 | Platelet activation, signaling and aggregation | 0.794981 | 0.100 |
| R-HSA-1257604 | PIP3 activates AKT signaling | 0.817128 | 0.088 |
| R-HSA-1483257 | Phospholipid metabolism | 0.817128 | 0.088 |
| R-HSA-195721 | Signaling by WNT | 0.820092 | 0.086 |
| R-HSA-5653656 | Vesicle-mediated transport | 0.825533 | 0.083 |
| R-HSA-168249 | Innate Immune System | 0.856819 | 0.067 |
| R-HSA-9006925 | Intracellular signaling by second messengers | 0.858487 | 0.066 |
| R-HSA-5668914 | Diseases of metabolism | 0.911655 | 0.040 |
| R-HSA-6798695 | Neutrophil degranulation | 0.925090 | 0.034 |
| R-HSA-109582 | Hemostasis | 0.932863 | 0.030 |
| R-HSA-382551 | Transport of small molecules | 0.973270 | 0.012 |
| R-HSA-556833 | Metabolism of lipids | 0.989650 | 0.005 |
| R-HSA-9709957 | Sensory Perception | 0.999084 | 0.000 |
| R-HSA-1430728 | Metabolism | 0.999998 | 0.000 |
Download
| kinase | JSD_mean | pearson_surrounding | kinase_max_IC_position | max_position_JSD |
|---|---|---|---|---|
KIS |
0.778 | 0.373 | 1 | 0.915 |
CDK1 |
0.775 | 0.386 | 1 | 0.925 |
CLK3 |
0.769 | 0.288 | 1 | 0.843 |
GRK1 |
0.758 | 0.213 | -2 | 0.854 |
JNK3 |
0.757 | 0.368 | 1 | 0.923 |
COT |
0.756 | 0.168 | 2 | 0.829 |
CDK18 |
0.755 | 0.344 | 1 | 0.920 |
JNK2 |
0.755 | 0.363 | 1 | 0.911 |
DYRK2 |
0.755 | 0.308 | 1 | 0.928 |
MTOR |
0.753 | 0.226 | 1 | 0.725 |
CDK3 |
0.753 | 0.311 | 1 | 0.905 |
DYRK4 |
0.753 | 0.324 | 1 | 0.922 |
P38G |
0.752 | 0.349 | 1 | 0.892 |
HIPK2 |
0.752 | 0.310 | 1 | 0.920 |
P38B |
0.752 | 0.356 | 1 | 0.905 |
JNK1 |
0.752 | 0.351 | 1 | 0.912 |
CDK8 |
0.751 | 0.313 | 1 | 0.915 |
CDK17 |
0.751 | 0.345 | 1 | 0.899 |
GRK7 |
0.750 | 0.209 | 1 | 0.624 |
CDK19 |
0.749 | 0.310 | 1 | 0.910 |
CLK2 |
0.747 | 0.204 | -3 | 0.585 |
MOS |
0.747 | 0.169 | 1 | 0.678 |
P38D |
0.746 | 0.354 | 1 | 0.893 |
ERK1 |
0.746 | 0.333 | 1 | 0.910 |
CDK13 |
0.744 | 0.298 | 1 | 0.924 |
IKKB |
0.744 | 0.124 | -2 | 0.685 |
NLK |
0.744 | 0.274 | 1 | 0.880 |
SRPK1 |
0.743 | 0.123 | -3 | 0.609 |
CDK5 |
0.742 | 0.301 | 1 | 0.930 |
CDK7 |
0.742 | 0.298 | 1 | 0.925 |
HIPK4 |
0.741 | 0.184 | 1 | 0.866 |
CDK12 |
0.740 | 0.299 | 1 | 0.917 |
NDR2 |
0.740 | 0.054 | -3 | 0.735 |
ERK5 |
0.740 | 0.184 | 1 | 0.807 |
IKKA |
0.739 | 0.105 | -2 | 0.669 |
CDK14 |
0.738 | 0.312 | 1 | 0.933 |
P38A |
0.738 | 0.307 | 1 | 0.921 |
CK1D |
0.737 | 0.177 | -3 | 0.466 |
HIPK1 |
0.737 | 0.263 | 1 | 0.932 |
PRPK |
0.736 | 0.055 | -1 | 0.895 |
ATR |
0.736 | 0.071 | 1 | 0.667 |
CDK16 |
0.736 | 0.310 | 1 | 0.906 |
PIM3 |
0.735 | 0.035 | -3 | 0.704 |
SKMLCK |
0.734 | 0.073 | -2 | 0.813 |
CDC7 |
0.734 | 0.017 | 1 | 0.618 |
ERK2 |
0.734 | 0.308 | 1 | 0.925 |
CDK10 |
0.734 | 0.281 | 1 | 0.935 |
CDK2 |
0.734 | 0.226 | 1 | 0.918 |
ICK |
0.733 | 0.147 | -3 | 0.692 |
DYRK1B |
0.732 | 0.263 | 1 | 0.936 |
CAMK2G |
0.732 | 0.036 | 2 | 0.797 |
CK1E |
0.731 | 0.133 | -3 | 0.504 |
GRK5 |
0.731 | 0.077 | -3 | 0.708 |
GSK3A |
0.731 | 0.175 | 4 | 0.399 |
PASK |
0.731 | 0.198 | -3 | 0.747 |
GRK4 |
0.730 | 0.088 | -2 | 0.819 |
BMPR1B |
0.730 | 0.111 | 1 | 0.579 |
RAF1 |
0.730 | -0.005 | 1 | 0.627 |
CK1A2 |
0.728 | 0.149 | -3 | 0.460 |
MAK |
0.728 | 0.246 | -2 | 0.736 |
SRPK3 |
0.728 | 0.083 | -3 | 0.586 |
CDKL1 |
0.728 | 0.041 | -3 | 0.653 |
PDHK4 |
0.727 | -0.055 | 1 | 0.687 |
CDK9 |
0.727 | 0.266 | 1 | 0.924 |
PRP4 |
0.727 | 0.220 | -3 | 0.669 |
GRK6 |
0.727 | 0.062 | 1 | 0.630 |
DSTYK |
0.726 | -0.018 | 2 | 0.834 |
BMPR2 |
0.724 | -0.025 | -2 | 0.803 |
CLK4 |
0.723 | 0.128 | -3 | 0.589 |
DYRK1A |
0.723 | 0.200 | 1 | 0.917 |
DYRK3 |
0.723 | 0.196 | 1 | 0.915 |
CAMK1B |
0.723 | -0.022 | -3 | 0.668 |
RIPK3 |
0.722 | -0.002 | 3 | 0.580 |
CK1A |
0.722 | 0.184 | -3 | 0.394 |
NEK6 |
0.722 | 0.008 | -2 | 0.756 |
CDKL5 |
0.722 | 0.043 | -3 | 0.646 |
DLK |
0.721 | 0.071 | 1 | 0.635 |
SRPK2 |
0.721 | 0.065 | -3 | 0.539 |
MLK1 |
0.721 | 0.011 | 2 | 0.737 |
IKKE |
0.720 | -0.047 | 1 | 0.541 |
ATM |
0.720 | 0.017 | 1 | 0.598 |
PRKX |
0.719 | 0.056 | -3 | 0.550 |
TBK1 |
0.719 | -0.074 | 1 | 0.553 |
GRK2 |
0.719 | 0.066 | -2 | 0.722 |
RSK2 |
0.719 | 0.012 | -3 | 0.621 |
CAMK2A |
0.719 | 0.044 | 2 | 0.823 |
GRK3 |
0.719 | 0.093 | -2 | 0.706 |
NDR1 |
0.719 | -0.024 | -3 | 0.685 |
MLK3 |
0.718 | 0.046 | 2 | 0.662 |
GCN2 |
0.718 | -0.114 | 2 | 0.746 |
PIM1 |
0.717 | 0.010 | -3 | 0.631 |
CHAK2 |
0.717 | -0.000 | -1 | 0.795 |
PKACG |
0.717 | 0.008 | -2 | 0.733 |
FAM20C |
0.717 | 0.032 | 2 | 0.625 |
HIPK3 |
0.716 | 0.210 | 1 | 0.906 |
NEK7 |
0.716 | -0.054 | -3 | 0.715 |
RSK4 |
0.715 | 0.031 | -3 | 0.625 |
LATS1 |
0.715 | 0.053 | -3 | 0.759 |
CAMK2B |
0.715 | 0.022 | 2 | 0.804 |
PKACB |
0.715 | 0.035 | -2 | 0.661 |
CAMLCK |
0.714 | -0.026 | -2 | 0.796 |
AURC |
0.714 | 0.029 | -2 | 0.660 |
CK1G1 |
0.714 | 0.098 | -3 | 0.486 |
MST4 |
0.714 | -0.041 | 2 | 0.771 |
MASTL |
0.713 | -0.078 | -2 | 0.742 |
TGFBR1 |
0.713 | 0.020 | -2 | 0.750 |
MEKK3 |
0.713 | 0.104 | 1 | 0.625 |
BCKDK |
0.713 | -0.073 | -1 | 0.796 |
PKN2 |
0.712 | -0.024 | -3 | 0.659 |
NIK |
0.712 | -0.076 | -3 | 0.697 |
DAPK2 |
0.712 | -0.038 | -3 | 0.694 |
TLK2 |
0.712 | 0.045 | 1 | 0.615 |
HUNK |
0.712 | -0.096 | 2 | 0.795 |
CDK6 |
0.712 | 0.262 | 1 | 0.923 |
PDHK1 |
0.711 | -0.158 | 1 | 0.648 |
CLK1 |
0.710 | 0.107 | -3 | 0.557 |
SMG1 |
0.710 | 0.005 | 1 | 0.630 |
ACVR2B |
0.710 | 0.033 | -2 | 0.731 |
WNK1 |
0.710 | -0.077 | -2 | 0.816 |
MLK2 |
0.710 | -0.018 | 2 | 0.738 |
CAMK2D |
0.710 | -0.044 | -3 | 0.677 |
PRKD1 |
0.710 | -0.040 | -3 | 0.697 |
GSK3B |
0.710 | 0.071 | 4 | 0.392 |
P90RSK |
0.709 | -0.026 | -3 | 0.625 |
ALK4 |
0.709 | -0.005 | -2 | 0.774 |
RIPK1 |
0.709 | -0.069 | 1 | 0.650 |
NUAK2 |
0.709 | -0.044 | -3 | 0.667 |
MSK1 |
0.709 | 0.013 | -3 | 0.600 |
PKN3 |
0.709 | -0.063 | -3 | 0.671 |
TGFBR2 |
0.709 | -0.063 | -2 | 0.741 |
P70S6KB |
0.708 | -0.034 | -3 | 0.621 |
LATS2 |
0.708 | -0.040 | -5 | 0.675 |
ALK2 |
0.708 | 0.016 | -2 | 0.776 |
CK2A2 |
0.708 | 0.067 | 1 | 0.518 |
ANKRD3 |
0.708 | -0.040 | 1 | 0.667 |
MLK4 |
0.708 | 0.006 | 2 | 0.654 |
DRAK1 |
0.707 | 0.008 | 1 | 0.612 |
MSK2 |
0.707 | -0.024 | -3 | 0.608 |
BMPR1A |
0.707 | 0.052 | 1 | 0.548 |
ACVR2A |
0.707 | 0.021 | -2 | 0.719 |
DNAPK |
0.707 | 0.012 | 1 | 0.568 |
AURA |
0.707 | 0.020 | -2 | 0.621 |
PINK1 |
0.706 | 0.031 | 1 | 0.800 |
PRKD2 |
0.706 | -0.029 | -3 | 0.628 |
TTBK2 |
0.706 | -0.038 | 2 | 0.640 |
ULK2 |
0.706 | -0.176 | 2 | 0.700 |
RSK3 |
0.706 | -0.036 | -3 | 0.607 |
PKCD |
0.706 | -0.038 | 2 | 0.697 |
MPSK1 |
0.705 | 0.104 | 1 | 0.702 |
PAK1 |
0.705 | -0.026 | -2 | 0.748 |
YSK4 |
0.705 | -0.019 | 1 | 0.578 |
MARK4 |
0.705 | -0.082 | 4 | 0.709 |
TAO3 |
0.705 | 0.071 | 1 | 0.632 |
PKCA |
0.705 | -0.003 | 2 | 0.628 |
PKCG |
0.704 | -0.020 | 2 | 0.656 |
MEK1 |
0.704 | -0.037 | 2 | 0.822 |
VRK2 |
0.703 | -0.016 | 1 | 0.728 |
CDK4 |
0.703 | 0.252 | 1 | 0.916 |
PLK1 |
0.703 | -0.044 | -2 | 0.690 |
PLK3 |
0.703 | -0.018 | 2 | 0.782 |
CK2A1 |
0.703 | 0.066 | 1 | 0.502 |
MYLK4 |
0.703 | -0.013 | -2 | 0.739 |
AKT2 |
0.703 | 0.007 | -3 | 0.531 |
GAK |
0.703 | 0.129 | 1 | 0.716 |
MST3 |
0.702 | 0.036 | 2 | 0.761 |
MAPKAPK2 |
0.701 | -0.034 | -3 | 0.595 |
PKCB |
0.701 | -0.029 | 2 | 0.638 |
ULK1 |
0.701 | -0.146 | -3 | 0.653 |
MOK |
0.700 | 0.161 | 1 | 0.893 |
PLK2 |
0.700 | 0.056 | -3 | 0.592 |
CK1G3 |
0.700 | 0.181 | -3 | 0.357 |
AMPKA1 |
0.699 | -0.103 | -3 | 0.688 |
IRE1 |
0.699 | -0.088 | 1 | 0.646 |
PKR |
0.698 | -0.078 | 1 | 0.673 |
NEK9 |
0.697 | -0.161 | 2 | 0.732 |
GCK |
0.697 | 0.073 | 1 | 0.630 |
PAK2 |
0.697 | -0.039 | -2 | 0.734 |
MEK5 |
0.697 | -0.034 | 2 | 0.765 |
CAMK4 |
0.696 | -0.091 | -3 | 0.641 |
WNK3 |
0.696 | -0.206 | 1 | 0.630 |
PKCZ |
0.695 | -0.054 | 2 | 0.671 |
NEK11 |
0.695 | 0.029 | 1 | 0.628 |
PKG2 |
0.695 | -0.004 | -2 | 0.675 |
MEKK2 |
0.695 | -0.010 | 2 | 0.725 |
AURB |
0.695 | -0.021 | -2 | 0.648 |
PAK3 |
0.694 | -0.073 | -2 | 0.732 |
PLK4 |
0.694 | -0.028 | 2 | 0.590 |
MNK1 |
0.693 | -0.039 | -2 | 0.733 |
QSK |
0.693 | -0.071 | 4 | 0.695 |
ERK7 |
0.692 | 0.066 | 2 | 0.458 |
AMPKA2 |
0.692 | -0.102 | -3 | 0.662 |
CK1G2 |
0.692 | 0.163 | -3 | 0.428 |
TSSK2 |
0.692 | -0.107 | -5 | 0.696 |
PKACA |
0.691 | 0.001 | -2 | 0.624 |
BRAF |
0.691 | -0.080 | -4 | 0.277 |
MAPKAPK3 |
0.691 | -0.107 | -3 | 0.623 |
SGK3 |
0.691 | -0.032 | -3 | 0.604 |
CAMK1G |
0.691 | -0.061 | -3 | 0.586 |
BRSK1 |
0.690 | -0.083 | -3 | 0.623 |
LKB1 |
0.690 | -0.013 | -3 | 0.709 |
ZAK |
0.690 | -0.047 | 1 | 0.578 |
MNK2 |
0.690 | -0.060 | -2 | 0.722 |
PIM2 |
0.690 | -0.035 | -3 | 0.575 |
NEK5 |
0.690 | -0.056 | 1 | 0.654 |
TLK1 |
0.689 | -0.052 | -2 | 0.767 |
NIM1 |
0.689 | -0.124 | 3 | 0.593 |
PKCH |
0.688 | -0.073 | 2 | 0.621 |
MARK3 |
0.688 | -0.069 | 4 | 0.646 |
TSSK1 |
0.688 | -0.106 | -3 | 0.714 |
QIK |
0.688 | -0.129 | -3 | 0.662 |
CHAK1 |
0.687 | -0.126 | 2 | 0.669 |
HPK1 |
0.687 | 0.021 | 1 | 0.619 |
SMMLCK |
0.686 | -0.051 | -3 | 0.637 |
PDK1 |
0.686 | -0.012 | 1 | 0.651 |
TAK1 |
0.686 | 0.050 | 1 | 0.610 |
DCAMKL1 |
0.686 | -0.070 | -3 | 0.623 |
YANK3 |
0.685 | 0.037 | 2 | 0.448 |
MEKK1 |
0.685 | -0.125 | 1 | 0.622 |
AKT1 |
0.684 | -0.017 | -3 | 0.553 |
IRE2 |
0.684 | -0.116 | 2 | 0.615 |
NEK8 |
0.684 | -0.067 | 2 | 0.714 |
PHKG1 |
0.684 | -0.100 | -3 | 0.669 |
PRKD3 |
0.683 | -0.086 | -3 | 0.571 |
SIK |
0.683 | -0.096 | -3 | 0.596 |
NEK2 |
0.683 | -0.157 | 2 | 0.698 |
DAPK1 |
0.682 | -0.004 | -3 | 0.621 |
CAMKK2 |
0.682 | -0.054 | -2 | 0.683 |
AKT3 |
0.682 | 0.008 | -3 | 0.495 |
MST2 |
0.682 | -0.034 | 1 | 0.610 |
CAMKK1 |
0.682 | -0.085 | -2 | 0.682 |
MARK2 |
0.681 | -0.096 | 4 | 0.613 |
STK33 |
0.681 | -0.037 | 2 | 0.618 |
BRSK2 |
0.681 | -0.130 | -3 | 0.634 |
PDHK4_TYR |
0.680 | 0.297 | 2 | 0.858 |
SLK |
0.680 | -0.008 | -2 | 0.677 |
PERK |
0.680 | -0.162 | -2 | 0.777 |
MARK1 |
0.679 | -0.106 | 4 | 0.664 |
DAPK3 |
0.679 | -0.032 | -3 | 0.636 |
OSR1 |
0.678 | 0.055 | 2 | 0.751 |
MAPKAPK5 |
0.678 | -0.121 | -3 | 0.567 |
SGK1 |
0.678 | -0.004 | -3 | 0.472 |
NUAK1 |
0.678 | -0.128 | -3 | 0.611 |
HRI |
0.678 | -0.187 | -2 | 0.763 |
PAK6 |
0.678 | -0.059 | -2 | 0.663 |
PKCE |
0.677 | -0.040 | 2 | 0.627 |
ALPHAK3 |
0.677 | 0.101 | -1 | 0.855 |
MELK |
0.677 | -0.154 | -3 | 0.630 |
TNIK |
0.676 | -0.041 | 3 | 0.650 |
TTBK1 |
0.676 | -0.084 | 2 | 0.577 |
DCAMKL2 |
0.676 | -0.078 | -3 | 0.620 |
MAP3K15 |
0.676 | -0.047 | 1 | 0.582 |
TAO2 |
0.675 | -0.101 | 2 | 0.740 |
KHS2 |
0.675 | -0.000 | 1 | 0.624 |
MINK |
0.675 | -0.063 | 1 | 0.600 |
CHK1 |
0.675 | -0.125 | -3 | 0.671 |
BMPR2_TYR |
0.674 | 0.160 | -1 | 0.874 |
WNK4 |
0.674 | -0.168 | -2 | 0.800 |
MAP2K6_TYR |
0.674 | 0.219 | -1 | 0.869 |
PDHK1_TYR |
0.674 | 0.225 | -1 | 0.861 |
P70S6K |
0.674 | -0.074 | -3 | 0.543 |
PDHK3_TYR |
0.674 | 0.200 | 4 | 0.776 |
SNRK |
0.674 | -0.177 | 2 | 0.609 |
LRRK2 |
0.673 | -0.083 | 2 | 0.750 |
PBK |
0.673 | -0.003 | 1 | 0.656 |
HGK |
0.672 | -0.074 | 3 | 0.657 |
EEF2K |
0.672 | -0.066 | 3 | 0.637 |
MAP2K4_TYR |
0.672 | 0.224 | -1 | 0.881 |
PKCT |
0.671 | -0.097 | 2 | 0.622 |
IRAK4 |
0.671 | -0.155 | 1 | 0.626 |
KHS1 |
0.671 | -0.043 | 1 | 0.603 |
MST1 |
0.670 | -0.077 | 1 | 0.601 |
PKCI |
0.670 | -0.087 | 2 | 0.641 |
SSTK |
0.669 | -0.094 | 4 | 0.683 |
BUB1 |
0.669 | 0.029 | -5 | 0.643 |
ROCK2 |
0.668 | -0.033 | -3 | 0.623 |
SBK |
0.668 | -0.007 | -3 | 0.427 |
CAMK1D |
0.667 | -0.084 | -3 | 0.512 |
PAK5 |
0.667 | -0.061 | -2 | 0.619 |
MEKK6 |
0.667 | -0.127 | 1 | 0.603 |
PAK4 |
0.666 | -0.044 | -2 | 0.623 |
VRK1 |
0.666 | -0.124 | 2 | 0.739 |
LOK |
0.666 | -0.087 | -2 | 0.708 |
YANK2 |
0.666 | 0.055 | 2 | 0.467 |
NEK4 |
0.665 | -0.154 | 1 | 0.611 |
MRCKA |
0.665 | -0.054 | -3 | 0.579 |
DMPK1 |
0.665 | -0.017 | -3 | 0.580 |
MRCKB |
0.664 | -0.047 | -3 | 0.562 |
IRAK1 |
0.662 | -0.203 | -1 | 0.710 |
TESK1_TYR |
0.661 | 0.040 | 3 | 0.686 |
MAP2K7_TYR |
0.661 | 0.032 | 2 | 0.803 |
NEK1 |
0.661 | -0.148 | 1 | 0.622 |
HASPIN |
0.661 | -0.026 | -1 | 0.653 |
YSK1 |
0.659 | -0.101 | 2 | 0.695 |
TTK |
0.659 | -0.032 | -2 | 0.738 |
PKMYT1_TYR |
0.658 | 0.017 | 3 | 0.661 |
CHK2 |
0.657 | -0.073 | -3 | 0.469 |
RIPK2 |
0.657 | -0.169 | 1 | 0.548 |
MYO3A |
0.655 | -0.043 | 1 | 0.624 |
CRIK |
0.655 | -0.033 | -3 | 0.569 |
MEK2 |
0.654 | -0.195 | 2 | 0.746 |
PHKG2 |
0.654 | -0.176 | -3 | 0.599 |
MYO3B |
0.652 | -0.074 | 2 | 0.702 |
FLT1 |
0.652 | 0.084 | -1 | 0.821 |
CAMK1A |
0.651 | -0.088 | -3 | 0.492 |
ASK1 |
0.651 | -0.080 | 1 | 0.569 |
LIMK2_TYR |
0.651 | -0.009 | -3 | 0.728 |
PKN1 |
0.651 | -0.100 | -3 | 0.549 |
ROCK1 |
0.650 | -0.060 | -3 | 0.574 |
TXK |
0.650 | 0.048 | 1 | 0.603 |
PKG1 |
0.649 | -0.056 | -2 | 0.607 |
ZAP70 |
0.649 | 0.157 | -1 | 0.816 |
PINK1_TYR |
0.649 | -0.116 | 1 | 0.686 |
SYK |
0.649 | 0.123 | -1 | 0.790 |
BIKE |
0.649 | -0.021 | 1 | 0.653 |
MET |
0.649 | 0.048 | 3 | 0.590 |
EPHA4 |
0.649 | 0.015 | 2 | 0.806 |
KIT |
0.648 | 0.030 | 3 | 0.608 |
EPHB4 |
0.648 | -0.024 | -1 | 0.835 |
EPHA6 |
0.647 | -0.044 | -1 | 0.839 |
STLK3 |
0.646 | -0.063 | 1 | 0.553 |
FER |
0.645 | -0.024 | 1 | 0.635 |
FGR |
0.644 | -0.036 | 1 | 0.659 |
PTK2 |
0.644 | 0.070 | -1 | 0.747 |
FGFR4 |
0.644 | 0.087 | -1 | 0.842 |
RET |
0.643 | -0.103 | 1 | 0.627 |
KDR |
0.643 | -0.008 | 3 | 0.565 |
FGFR3 |
0.643 | 0.029 | 3 | 0.610 |
MST1R |
0.643 | -0.112 | 3 | 0.606 |
ABL2 |
0.643 | -0.020 | -1 | 0.833 |
LIMK1_TYR |
0.643 | -0.100 | 2 | 0.751 |
FGFR2 |
0.643 | -0.023 | 3 | 0.633 |
CSF1R |
0.642 | -0.053 | 3 | 0.589 |
BMX |
0.642 | 0.049 | -1 | 0.815 |
FYN |
0.642 | 0.035 | -1 | 0.768 |
INSRR |
0.642 | -0.037 | 3 | 0.565 |
WEE1_TYR |
0.641 | 0.001 | -1 | 0.853 |
TAO1 |
0.641 | -0.128 | 1 | 0.561 |
YES1 |
0.640 | -0.051 | -1 | 0.794 |
SRMS |
0.639 | -0.045 | 1 | 0.605 |
JAK3 |
0.639 | -0.066 | 1 | 0.608 |
MATK |
0.639 | 0.038 | -1 | 0.831 |
NEK3 |
0.639 | -0.206 | 1 | 0.587 |
ABL1 |
0.638 | -0.042 | -1 | 0.820 |
DDR1 |
0.637 | -0.146 | 4 | 0.696 |
EGFR |
0.637 | 0.026 | 1 | 0.509 |
EPHB1 |
0.637 | -0.053 | 1 | 0.593 |
LCK |
0.637 | -0.029 | -1 | 0.785 |
ERBB2 |
0.637 | -0.029 | 1 | 0.584 |
EPHA3 |
0.636 | -0.032 | 2 | 0.759 |
ITK |
0.636 | -0.030 | -1 | 0.777 |
BLK |
0.636 | -0.015 | -1 | 0.767 |
TNK2 |
0.636 | -0.069 | 3 | 0.572 |
JAK2 |
0.635 | -0.121 | 1 | 0.607 |
EPHB3 |
0.635 | -0.059 | -1 | 0.810 |
EPHB2 |
0.634 | -0.059 | -1 | 0.812 |
AAK1 |
0.634 | 0.008 | 1 | 0.596 |
TYRO3 |
0.634 | -0.143 | 3 | 0.588 |
HCK |
0.633 | -0.085 | -1 | 0.781 |
ROS1 |
0.632 | -0.152 | 3 | 0.555 |
EPHA7 |
0.632 | -0.037 | 2 | 0.781 |
TYK2 |
0.632 | -0.225 | 1 | 0.609 |
NTRK3 |
0.632 | -0.003 | -1 | 0.865 |
SRC |
0.631 | -0.014 | -1 | 0.769 |
TEK |
0.631 | -0.074 | 3 | 0.551 |
EPHA5 |
0.631 | -0.023 | 2 | 0.789 |
FGFR1 |
0.630 | -0.090 | 3 | 0.574 |
EPHA8 |
0.629 | -0.026 | -1 | 0.800 |
NTRK1 |
0.629 | -0.085 | -1 | 0.865 |
MERTK |
0.628 | -0.077 | 3 | 0.578 |
FLT4 |
0.628 | -0.066 | 3 | 0.576 |
EPHA2 |
0.628 | 0.023 | -1 | 0.809 |
LYN |
0.628 | -0.045 | 3 | 0.529 |
TEC |
0.628 | -0.069 | -1 | 0.736 |
ERBB4 |
0.627 | 0.017 | 1 | 0.524 |
CSK |
0.626 | -0.041 | 2 | 0.777 |
FLT3 |
0.625 | -0.164 | 3 | 0.580 |
JAK1 |
0.624 | -0.098 | 1 | 0.561 |
NEK10_TYR |
0.623 | -0.140 | 1 | 0.540 |
PTK2B |
0.622 | -0.064 | -1 | 0.756 |
INSR |
0.622 | -0.093 | 3 | 0.537 |
AXL |
0.622 | -0.143 | 3 | 0.587 |
PDGFRB |
0.621 | -0.195 | 3 | 0.600 |
LTK |
0.621 | -0.105 | 3 | 0.551 |
BTK |
0.621 | -0.157 | -1 | 0.752 |
NTRK2 |
0.620 | -0.131 | 3 | 0.567 |
PTK6 |
0.620 | -0.120 | -1 | 0.775 |
DDR2 |
0.620 | -0.086 | 3 | 0.570 |
ALK |
0.619 | -0.122 | 3 | 0.525 |
TNK1 |
0.618 | -0.157 | 3 | 0.572 |
IGF1R |
0.617 | -0.044 | 3 | 0.499 |
FRK |
0.617 | -0.113 | -1 | 0.776 |
PDGFRA |
0.614 | -0.222 | 3 | 0.594 |
TNNI3K_TYR |
0.613 | -0.154 | 1 | 0.626 |
EPHA1 |
0.608 | -0.182 | 3 | 0.565 |
FES |
0.607 | -0.033 | -1 | 0.807 |
MUSK |
0.602 | -0.114 | 1 | 0.521 |